<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristin M Leiferman, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John J Zone, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Abena O Ofori, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 30, 2021.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H590249"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Bullous pemphigoid and mucous membrane pemphigoid (MMP) are autoimmune blistering diseases that most commonly arise in older adults  (<a class="graphic graphic_picture graphicRef70352 graphicRef79112 graphicRef54541 graphicRef73874 graphicRef52208 graphicRef63997" href="/z/d/graphic/70352.html" rel="external">picture 1A-F</a>). These disorders are characterized by subepithelial blister formation and the deposition of immunoglobulins and complement within the epidermal and/or mucosal basement membrane zone. Historically, the term "cicatricial pemphigoid" also referred to MMP.</p><p>Although both bullous pemphigoid and MMP may affect skin and mucosa, the classical clinical findings in bullous pemphigoid are tense, fluid-filled bullae on skin, whereas the prevailing clinical feature in MMP is mucosal involvement. In MMP, inflamed and eroded mucosa is characteristic, involving any or all of the oral cavity, ocular conjunctiva, nose, pharynx, larynx, esophagus, anus, and genital mucous membranes.</p><p>The clinical features and diagnosis of bullous pemphigoid and MMP will be reviewed here  (<a class="graphic graphic_algorithm graphicRef120171" href="/z/d/graphic/120171.html" rel="external">algorithm 1</a>). The epidemiology, pathogenesis, and treatment of these disorders, as well as greater detail on the ocular form of MMP, are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/16864.html" rel="external">"Epidemiology and pathogenesis of bullous pemphigoid and mucous membrane pemphigoid"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15297.html" rel="external">"Management and prognosis of bullous pemphigoid"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/83575.html" rel="external">"Management of mucous membrane pemphigoid"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15590.html" rel="external">"Ocular cicatricial pemphigoid"</a>.)</p><p></p><p>Pemphigoid gestationis, a rare form of pemphigoid associated with pregnancy, is reviewed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5564.html" rel="external">"Dermatoses of pregnancy", section on 'Pemphigoid gestationis'</a>.)</p><p></p><p class="headingAnchor" id="H53290498"><span class="h1">CLINICAL FEATURES OF BULLOUS PEMPHIGOID</span></p><p class="headingAnchor" id="H1059292142"><span class="h2">Clinical features</span><span class="headingEndMark"> — </span>Important clinical features for bullous pemphigoid include signs and symptoms that may precede blister formation, blister morphology, and the distribution of skin involvement:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prodromal phase</strong> – A prodromal phase lasting weeks to months may precede the development of cutaneous bullae [<a href="#rid1">1,2</a>]. The prodromal phase may present with pruritic, eczematous, papular, or urticaria-like skin lesions  (<a class="graphic graphic_picture graphicRef80385" href="/z/d/graphic/80385.html" rel="external">picture 1G</a>) [<a href="#rid3">3,4</a>]. Some patients with bullous pemphigoid never develop blistering.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lesion morphology</strong> – When blisters develop, the classical lesion is a 1 to 3 cm, tense bulla on an erythematous, urticarial, or noninflammatory base, and blisters may be numerous and widespread  (<a class="graphic graphic_picture graphicRef54541 graphicRef70352 graphicRef79112" href="/z/d/graphic/54541.html" rel="external">picture 1A-C</a>) [<a href="#rid5">5</a>]. The tense quality of the bullae differentiates lesions of bullous pemphigoid from the flaccid bullae of pemphigus, of which the Nikolsky sign is a moderately sensitive, but highly specific, finding  (<a class="graphic graphic_picture graphicRef53425" href="/z/d/graphic/53425.html" rel="external">picture 2A</a>) [<a href="#rid1">1,6</a>]. (See  <a class="medical medical_review" href="/z/d/html/83684.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of pemphigus"</a>.)</p><p></p><p class="bulletIndent1">Eventually, the bullae rupture, leaving moist erosions and crusts that resolve without scarring. When mainly erosions are present, it may be difficult to clinically distinguish bullous pemphigoid and pemphigus  (<a class="graphic graphic_picture graphicRef63170" href="/z/d/graphic/63170.html" rel="external">picture 2B</a>). </p><p></p><p class="bulletIndent1">Associated pruritus is common and can be severe [<a href="#rid7">7-9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Distribution</strong> – The trunk, extremity flexures, and axillary and inguinal folds are common sites for cutaneous involvement  (<a class="graphic graphic_picture graphicRef72866 graphicRef78910 graphicRef59590" href="/z/d/graphic/72866.html" rel="external">picture 3A-C</a>) [<a href="#rid10">10</a>]. Mucosal lesions are present in 10 to 30 percent of patients  (<a class="graphic graphic_picture graphicRef66179" href="/z/d/graphic/66179.html" rel="external">picture 4</a>) [<a href="#rid1">1,2,5,11</a>]. The oral mucosa is the most frequent location of mucosal involvement. Less frequently, bullous pemphigoid involves other mucosal sites, such as the larynx, genitals, and anus [<a href="#rid11">11</a>]. Nail changes may also develop [<a href="#rid12">12,13</a>].</p><p></p><p class="bulletIndent1">Localized forms of bullous pemphigoid occur and account for up to 30 percent of cases [<a href="#rid14">14</a>]. Examples include disease limited to the lower legs  (<a class="graphic graphic_picture graphicRef71249" href="/z/d/graphic/71249.html" rel="external">picture 1H</a>) [<a href="#rid14">14-18</a>], anogenital region [<a href="#rid19">19,20</a>], peristomal skin [<a href="#rid21">21,22</a>], or sites of incidental or iatrogenic trauma (eg, radiation therapy) [<a href="#rid23">23-29</a>]. Disease that begins in localized areas may remain localized or may progress to generalized involvement [<a href="#rid14">14,30</a>].</p><p></p><p class="headingAnchor" id="H3944707620"><span class="h2">Clinical variants</span><span class="headingEndMark"> — </span>Clinical variants of bullous pemphigoid include nonbullous presentations, lichen planus pemphigoides, and other rare variants:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonbullous presentations</strong> – Nonbullous presentations of bullous pemphigoid include eczematous, urticarial, and prurigo-like (pemphigoid nodularis) presentations, as well as bullous pemphigoid presenting as pruritus without any primary skin lesions (pruritic nonbullous pemphigoid, bullous pemphigoid as pruritus in older adults). In such cases, the diagnosis is based upon consistent laboratory findings [<a href="#rid2">2,31-34</a>]. (See <a class="local">'Confirmatory testing'</a> below.)</p><p></p><p class="bulletIndent1">It is estimated that approximately 20 percent of patients with bullous pemphigoid present with nonbullous manifestations [<a href="#rid35">35</a>]. In a retrospective study of 69 patients with nonbullous pemphigoid, the most common presentations included pruritic papules or nodules (37 percent of patients) and pruritus without primary skin lesions (22 percent of patients) [<a href="#rid34">34</a>]. Progression to blistering disease eventually occurs in some patients. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lichen planus pemphigoides</strong> – Lichen planus pemphigoides is a rare variant of bullous pemphigoid. It is postulated that the cellular inflammatory process, which occurs at the basement membrane zone in lichen planus, results in exposure of basement membrane zone antigens, leading to subsequent development of basement membrane zone antibodies [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent1">Patients with lichen planus pemphigoides typically present with bullae in sites of previously normal-appearing skin or mucosa. The bullae usually appear weeks to months after the onset of lichen planus [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/z/d/html/5662.html" rel="external">"Lichen planus", section on 'Overlap syndromes'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other rare variants</strong> – Examples of rare variants include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pemphigoid vegetans</strong> – Verruciform plaques in intertriginous areas [<a href="#rid37">37,38</a>]</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dyshidrosiform pemphigoid</strong> – Palmar and/or plantar skin involvement (resembling dyshidrotic eczema), often hemorrhagic  (<a class="graphic graphic_picture graphicRef50357" href="/z/d/graphic/50357.html" rel="external">picture 1I</a>) [<a href="#rid39">39,40</a>]</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Vesicular bullous pemphigoid</strong> – Lesions resembling dermatitis herpetiformis [<a href="#rid41">41</a>]</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bullous pemphigoid occurring in association with transient palmoplantar keratoderma</strong> [<a href="#rid42">42</a>] (see  <a class="medical medical_review" href="/z/d/html/110147.html" rel="external">"Palmoplantar keratoderma", section on 'Acquired palmoplantar keratoderma'</a>)</p><p></p><p class="headingAnchor" id="H53290512"><span class="h1">CLINICAL FEATURES OF MUCOUS MEMBRANE PEMPHIGOID</span><span class="headingEndMark"> — </span>MMP represents a group of heterogeneous, chronic, subepithelial, blistering disorders that primarily affect mucosal surfaces [<a href="#rid43">43</a>]. Mucosal involvement, with or without associated cutaneous involvement, characterizes MMP.</p><p>Some authors also consider cases of linear IgA bullous dermatosis and epidermolysis bullosa acquisita that primarily involve the mucous membranes as forms of MMP [<a href="#rid43">43</a>]. However, we view these diagnoses as distinct entities. (See  <a class="medical medical_review" href="/z/d/html/15301.html" rel="external">"Linear IgA bullous dermatosis"</a> and  <a class="medical medical_review" href="/z/d/html/15299.html" rel="external">"Epidermolysis bullosa acquisita"</a>.)</p><p class="headingAnchor" id="H2600514610"><span class="h2">Mucosal features</span><span class="headingEndMark"> — </span>Characteristic clinical features of MMP include mucosal erosions and scarring:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lesion morphology and distribution</strong> – MMP typically presents as relapsing and remitting, mucosal inflammation and erosions  (<a class="graphic graphic_picture graphicRef73874 graphicRef52208 graphicRef63997" href="/z/d/graphic/73874.html" rel="external">picture 1D-F</a>). The detection of intact vesicles or bullae on mucosa is uncommon. Compared with the mucosal lesions of pemphigus  (<a class="graphic graphic_picture graphicRef57924" href="/z/d/graphic/57924.html" rel="external">picture 2C</a>), pain associated with oral MMP lesions is usually less intense [<a href="#rid2">2</a>]. </p><p></p><p class="bulletIndent1">The oral cavity is the most common site of involvement. In a report that summarized the sites of involvement in 457 patients with MMP, the frequency of affected sites was as follows [<a href="#rid44">44</a>]: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Oral mucosa (85 percent)</p><p class="bulletIndent2"><span class="glyph">•</span>Ocular conjunctiva (64 percent)</p><p class="bulletIndent2"><span class="glyph">•</span>Skin (24 percent)</p><p class="bulletIndent2"><span class="glyph">•</span>Pharynx (19 percent)</p><p class="bulletIndent2"><span class="glyph">•</span>External genitalia (17 percent)</p><p class="bulletIndent2"><span class="glyph">•</span>Nasal mucosa (15 percent)</p><p class="bulletIndent2"><span class="glyph">•</span>Larynx (8 percent)</p><p class="bulletIndent2"><span class="glyph">•</span>Anus (4 percent)</p><p class="bulletIndent2"><span class="glyph">•</span>Esophagus (4 percent)</p><p></p><p class="bulletIndent1">In the oral cavity, the gingival and buccal mucosae are most commonly affected. Gingival disease usually manifests as a desquamative or erosive gingivitis  (<a class="graphic graphic_picture graphicRef73874" href="/z/d/graphic/73874.html" rel="external">picture 1D</a>) and, in mild cases, may manifest only with gingival erythema and edema [<a href="#rid45">45</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Scarring</strong> – Scarring is a common consequence of MMP that distinguishes this variant from mucosal involvement in bullous pemphigoid, which typically does not scar. Reticulated, white striations representing mucosal fibrosis are often present at sites of healed lesions, and functional limitations secondary to scarring may occur [<a href="#rid2">2,45</a>]. As examples, MMP involving the ocular mucosa can lead to symblepharon, ankyloblepharon, and eventual blindness, and progressive laryngeal and tracheal involvement can result in asphyxiation  (<a class="graphic graphic_picture graphicRef54207" href="/z/d/graphic/54207.html" rel="external">picture 5</a>) [<a href="#rid45">45</a>]. (See  <a class="medical medical_review" href="/z/d/html/15590.html" rel="external">"Ocular cicatricial pemphigoid", section on 'Clinical manifestations'</a>.)</p><p></p><p class="headingAnchor" id="H1154184092"><span class="h2">Cutaneous features</span><span class="headingEndMark"> — </span>Cutaneous involvement in patients with MMP typically involves the scalp, face, or upper trunk. Blistering lesions resemble those seen in bullous pemphigoid but, similar to mucosal lesions of MMP, often heal with scarring.</p><p class="headingAnchor" id="H3867557"><span class="h1">ASSOCIATED DISORDERS</span><span class="headingEndMark"> — </span>Patients with bullous pemphigoid often have multiple comorbidities [<a href="#rid46">46-53</a>]. In a case-control study that included 105 patients with bullous pemphigoid and 315 matched controls, patients with bullous pemphigoid were more likely to have two or more other chronic diseases (84 versus 65 percent) [<a href="#rid46">46</a>]. In particular, multiple studies have evaluated associations between bullous pemphigoid and neurologic disorders and between MMP and malignancy.</p><p class="headingAnchor" id="H3867564"><span class="h2">Neurologic disorders</span><span class="headingEndMark"> — </span>Examples of neurologic disorders that may be associated with bullous pemphigoid include dementia, Parkinson disease, bipolar disorder, stroke, and multiple sclerosis:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evidence</strong> – Associations between bullous pemphigoid and neurologic disorders have been reported in observational studies and case reports [<a href="#rid47">47,53-65</a>]. In a hospital-based, prospective, case-control study of 201 patients with bullous pemphigoid and 345 matched controls, dementia, Parkinson disease, and unipolar or bipolar disorder were among the identified independent risk factors for this disease [<a href="#rid56">56</a>]. In addition, a population-based, case-control study of 868 patients with bullous pemphigoid and more than 3400 controls found that patients with pre-existing diagnoses of dementia, Parkinson disease, or stroke were significantly more likely to develop bullous pemphigoid [<a href="#rid55">55</a>]. Further, a case-control study with more than 5000 patients with multiple sclerosis and over 26,000 controls supported an association of bullous pemphigoid and this disease [<a href="#rid66">66</a>]. Neurologic cancers are included in the range of neurologic disorders associated with bullous pemphigoid [<a href="#rid67">67</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rationale</strong> – Homology between bullous pemphigoid antigens in the skin and neuronal antigens in the central nervous system has been proposed as a cause for the observed link between bullous pemphigoid and neurologic disease, along with a genetic predisposition [<a href="#rid68">68-72</a>]. However, further studies are necessary to explore the relationship between these disorders. (See  <a class="medical medical_review" href="/z/d/html/16864.html" rel="external">"Epidemiology and pathogenesis of bullous pemphigoid and mucous membrane pemphigoid", section on 'Epitope spreading'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient evaluation</strong> – Each patient visit should include assessment of neurologic signs and symptoms in the review of systems, with referral to neurology if positive findings are identified.</p><p></p><p class="headingAnchor" id="H3867571"><span class="h2">Malignancy</span><span class="headingEndMark"> — </span>MMP can occur in association with malignancy. A relatively strong association exists between MMP with antibodies directed against laminin 332 (previously known as laminin 5 and epiligrin) and internal malignancy  (<a class="graphic graphic_figure graphicRef67891" href="/z/d/graphic/67891.html" rel="external">figure 1</a>). The relationship between bullous pemphigoid and malignancy is less clear:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mucous membrane pemphigoid</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Evidence</strong> – In a cohort of 35 patients with anti-laminin 332 MMP (diagnosed with immunoprecipitation), 10 patients (29 percent) developed solid organ malignancies, 7 of which were diagnosed within 14 months after a diagnosis of MMP [<a href="#rid73">73</a>]. Occurrences of non-Hodgkin lymphoma and cutaneous T cell lymphoma have also been reported in individual patients with anti-laminin 332 MMP [<a href="#rid74">74</a>]. In a series of 55 patients with anti-laminin 332 MMP, 14 percent had associated malignancies of various tissues, some with multiple tumors [<a href="#rid75">75</a>].</p><p></p><p class="bulletIndent2">There may also be an increased risk for malignancy in patients with other forms of MMP, although the degree of risk is unclear. In a case series of 22 patients with MMP from a single institution, four patients (18 percent) had an associated cancer [<a href="#rid76">76</a>]. All four patients were negative for laminin 332 antibodies.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Rationale</strong> – The pathophysiologic relationship of MMP with antibodies against laminin 332 to cancer is unknown. However, expression of laminin 332 has been detected in malignant cells, and laminin 332 appears to be capable of promoting tumor cell growth, invasion, and metastasis [<a href="#rid74">74,77</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Recognition and evaluation of patients at risk</strong> – The clinical manifestations of MMP in patients with laminin 332 antibodies are similar to the features of MMP with other antibody profiles. Therefore, clinical examination cannot reliably distinguish anti-laminin 332 MMP from other forms of MMP. </p><p></p><p class="bulletIndent2">Since diagnostic laboratory testing for laminin 332 antibodies is not commercially available, suspicion for laminin 332 is primarily based upon serologic findings. Although not exclusive to laminin 332 MMP, the detection of serum antibodies bound to the dermal side of basement membrane zone-split (salt-split) skin suggests the possibility of this diagnosis. (See <a class="local">'Indirect immunofluorescence assay'</a> below.)</p><p></p><p class="bulletIndent2">Until definitive testing for laminin 332 antibodies becomes available, we advise that patients with MMP in whom serum studies reveal antibodies bound to the dermal side of basement membrane zone-split skin undergo age- and sex-appropriate cancer screening. Additional evaluation for malignancy should be performed as indicated based upon a review of symptoms, physical examination, and the results of age-appropriate screening. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bullous pemphigoid</strong> – While some studies support an association, others have failed to find a significant increase in malignancy risk, attributing occurrences of malignancy to age rather than bullous pemphigoid [<a href="#rid53">53,78,79</a>]. A systematic review and meta-analysis of observational studies did not find an association of bullous pemphigoid with malignancy overall but found an association between bullous pemphigoid and hematologic malignancies [<a href="#rid80">80</a>]. Another meta-analysis of studies assessing the association between bullous pemphigoid and malignancy found a greater event rate of malignancy in patients with bullous pemphigoid compared with controls and a slightly lower event rate for malignancy in Asian studies compared with European studies [<a href="#rid81">81</a>].</p><p></p><p class="bulletIndent1">In our practice, we evaluate young and middle-aged patients with bullous pemphigoid for underlying malignancy particularly when they present with severe or refractory disease, present with symptoms or signs in organ systems other than skin, or if there is a family history of genetically associated malignancy. Our typical approach is to ensure age- and sex-appropriate cancer screening. Additional evaluation for malignancy is based upon a review of symptoms, physical examination, and the results of age-appropriate screening.</p><p></p><p class="headingAnchor" id="H785112"><span class="h1">DISEASE COURSE</span><span class="headingEndMark"> — </span>Bullous pemphigoid is a chronic disorder characterized by exacerbations and remissions over the course of months to years. However, in some patients, the disease is self-limited, resulting in disease remissions within a few years. (See  <a class="medical medical_review" href="/z/d/html/15297.html" rel="external">"Management and prognosis of bullous pemphigoid", section on 'Prognosis'</a>.)</p><p>In the absence of treatment, MMP is usually a chronic, progressive disease that results in functionally limiting or, in some cases (eg, those with airway involvement), life-threatening disease [<a href="#rid45">45</a>]. The clinical course and prognosis of ocular MMP is reviewed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/15590.html" rel="external">"Ocular cicatricial pemphigoid", section on 'Clinical manifestations'</a> and  <a class="medical medical_review" href="/z/d/html/15590.html" rel="external">"Ocular cicatricial pemphigoid", section on 'Prognosis and cessation of therapy'</a>.)</p><p class="headingAnchor" id="H20007006"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>Although clinical findings may strongly suggest bullous pemphigoid or MMP, other disorders present with similar mucocutaneous lesions, and nonbullous or other less typical presentations can occur  (<a class="graphic graphic_table graphicRef69192" href="/z/d/graphic/69192.html" rel="external">table 1</a>). Thus, confirmation of the diagnosis requires the careful interpretation of both clinical and laboratory findings. (See <a class="local">'Differential diagnosis'</a> below.)</p><p class="headingAnchor" id="H587825"><span class="h2">Recognition of suggestive clinical findings</span><span class="headingEndMark"> — </span>Bullous pemphigoid or MMP should be strongly considered when patients over the age of 60 years present with one or more of the following clinical features: </p><p class="bulletIndent1"><span class="glyph">●</span>Blistering skin disease characterized by the presence of tense blisters and erosions that occur without another identifiable cause</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Desquamative gingivitis or mucositis involving oral, ocular, nasal, genital, anal, pharyngeal, laryngeal, and/or esophageal mucosae</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Unexplained pruritus; pruritic, eczematous eruptions; or urticarial plaques</p><p></p><p>The possibility of bullous pemphigoid or MMP should also be considered in the evaluation of younger adults, children, and infants with suggestive signs or symptoms in the absence of another identifiable cause  (<a class="graphic graphic_picture graphicRef58359" href="/z/d/graphic/58359.html" rel="external">picture 1J</a>) [<a href="#rid82">82-84</a>]. (See  <a class="medical medical_review" href="/z/d/html/16864.html" rel="external">"Epidemiology and pathogenesis of bullous pemphigoid and mucous membrane pemphigoid", section on 'Epidemiology'</a> and <a class="local">'Clinical features of bullous pemphigoid'</a> above and <a class="local">'Clinical features of mucous membrane pemphigoid'</a> above.)</p><p>Laboratory assessment is indicated when clinical findings suggest bullous pemphigoid or MMP. (See <a class="local">'Confirmatory testing'</a> below.)</p><p class="headingAnchor" id="H20007014"><span class="h2">Confirmatory testing</span><span class="headingEndMark"> — </span>The principal studies used in the evaluation of patients with lesions suspicious for bullous pemphigoid or MMP include biopsy for routine histopathologic examination, biopsy for direct immunofluorescence (DIF) microscopy, and serum tests to detect circulating anti-basement membrane zone antibodies (indirect immunofluorescence [IIF] assay and enzyme-linked immunosorbent assay [ELISA])  (<a class="graphic graphic_table graphicRef57402" href="/z/d/graphic/57402.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H404213"><span class="h3">Test selection</span><span class="headingEndMark"> — </span>An algorithm depicting the approach to the diagnosis of patients with clinical findings suspicious for bullous pemphigoid or MMP is provided  (<a class="graphic graphic_algorithm graphicRef120171" href="/z/d/graphic/120171.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H3037681556"><span class="h4">Initial tests</span><span class="headingEndMark"> — </span>In patients with clinical findings suggestive of bullous pemphigoid or MMP, we begin the laboratory assessment by obtaining both of the following  (<a class="graphic graphic_algorithm graphicRef120171" href="/z/d/graphic/120171.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lesional</strong> tissue specimen for routine (fixed tissue) histopathology</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Perilesional</strong> tissue specimen for DIF examinations</p><p></p><p>Routine histopathologic examination provides diagnostic support through detection of pathologic findings that are consistent or inconsistent with bullous pemphigoid or MMP. DIF detects characteristic immunoglobulin and complement deposition within the skin or mucous membrane. (See <a class="local">'Tissue biopsy'</a> below and <a class="local">'Routine histopathologic examination'</a> below and <a class="local">'Direct immunofluorescence'</a> below.)</p><p class="headingAnchor" id="H1617089863"><span class="h4">Subsequent tests</span><span class="headingEndMark"> — </span>We perform serum testing to detect circulating anti-basement membrane zone antibodies in all patients with histopathologic and DIF findings consistent with bullous pemphigoid or MMP. We also perform serum testing when strong clinical suspicion for bullous pemphigoid or MMP remains despite histopathologic or DIF findings that are not entirely consistent with bullous pemphigoid or MMP  (<a class="graphic graphic_algorithm graphicRef120171" href="/z/d/graphic/120171.html" rel="external">algorithm 1</a>).</p><p>We typically obtain both of the following types of serum tests:</p><p class="bulletIndent1"><span class="glyph">●</span>IIF assays on human basement membrane zone-split skin and monkey esophagus substrates</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bullous pemphigoid antigen 180 (BP180) and bullous pemphigoid antigen 230 (BP230) immunoglobulin G (IgG) antibody ELISAs</p><p></p><p>IIF plays an important role in diagnosis, as it allows for the differentiation of bullous pemphigoid from other autoimmune blistering diseases, enables presumptive identification of patients at risk for malignancy-associated laminin 332 MMP, and supports a diagnosis when DIF is negative or not feasible  (<a class="graphic graphic_algorithm graphicRef120171" href="/z/d/graphic/120171.html" rel="external">algorithm 1</a>) [<a href="#rid35">35,85,86</a>]. </p><p>ELISA testing provides additional diagnostic support and may have value for assessing the response to treatment. ELISA testing may be more sensitive than IIF for the diagnosis of bullous pemphigoid and MMP but can be negative in some patients with bullous pemphigoid or MMP because of the limited display of potential target epitopes in the assays  (<a class="graphic graphic_algorithm graphicRef120171" href="/z/d/graphic/120171.html" rel="external">algorithm 1</a>) [<a href="#rid85">85,86</a>]. (See <a class="local">'Indirect immunofluorescence assay'</a> below and <a class="local">'Enzyme-linked immunosorbent assay'</a> below.)</p><p>A diagnostic accuracy study supports routine performance of both DIF and IIF for the standard-of-care diagnostic evaluation of bullous pemphigoid. In an analysis of 1125 patients with suspected bullous pemphigoid in which 343 received a pemphigoid diagnosis, DIF was the most sensitive diagnostic test (sensitivity of 88.3 percent, 95% CI 84.5-91.3 percent and specificity of 99.2 percent, 95% CI 98.3-99.7 percent), and IIF on human basement membrane zone-split (salt-split) skin was less sensitive but highly specific (sensitivity of 77 percent, 95% CI 72.2-81.1 and specificity of 99.9 percent, 95% CI 99.3-100 percent) [<a href="#rid35">35</a>]. IIF complemented DIF, exhibiting positivity in most cases of bullous pemphigoid with negative DIF findings. Based upon the study results, the authors proposed at least two of the following three characteristics as minimal diagnostic criteria:</p><p class="bulletIndent1"><span class="glyph">●</span>Pruritus and/or predominant, cutaneous blisters</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Linear IgG and/or C3 deposits by DIF on a skin biopsy specimen</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Positive epidermal (roof) side IgG basement membrane zone antibody localization on split skin substrate by IIF with a serum specimen</p><p></p><p class="headingAnchor" id="H554282"><span class="h3">Tissue biopsy</span><span class="headingEndMark"> — </span>Lesional biopsies for routine histopathologic examination and perilesional skin biopsies for DIF can support a diagnosis of bullous pemphigoid or MMP. (See <a class="local">'Test selection'</a> above.)</p><p class="headingAnchor" id="H206688414"><span class="h4">General principles</span><span class="headingEndMark"> — </span>Separate specimens are optimal for routine histopathologic examination and DIF because of differences in the preferred biopsy location (lesional versus perilesional) and tissue handling (preservation in formalin versus specialized transport medium)  (<a class="graphic graphic_table graphicRef57402" href="/z/d/graphic/57402.html" rel="external">table 2</a>). We typically obtain two 4 mm punch biopsies. Careful splitting of a 5 or 6 mm punch biopsy specimen or a shave biopsy specimen into lesional and perilesional specimens is an alternative. (See  <a class="medical medical_review" href="/z/d/html/5577.html" rel="external">"Skin biopsy techniques", section on 'Punch biopsy'</a> and  <a class="medical medical_review" href="/z/d/html/13684.html" rel="external">"Approach to the patient with cutaneous blisters", section on 'Skin biopsy'</a>.)</p><p>If only one small specimen can be obtained, the preferred test to perform is DIF.</p><p class="headingAnchor" id="H4988524"><span class="h4">Routine histopathologic examination</span><span class="headingEndMark"> — </span>Histopathologic examination supports a diagnosis of bullous pemphigoid or MMP through the detection of consistent histopathologic findings but is not sufficient for diagnosis:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Biopsy technique</strong> – Skin biopsies for routine histopathologic examination (ie, hematoxylin and eosin [H&amp;E] staining) should be taken from <strong>lesional</strong> tissue, preferably of an intact vesicle or the edge of an intact bulla  (<a class="graphic graphic_table graphicRef57402" href="/z/d/graphic/57402.html" rel="external">table 2</a>). The specimen should include the blister edge and the immediately adjacent tissue. If blisters are absent, the lesional biopsy may be taken from other involved sites of inflammation (eg, urticarial or eczematous lesions or inflamed areas of mucosa).</p><p></p><p class="bulletIndent1">Care should be taken to avoid excessive torsion and crushing, which may alter tissue cleavage planes and increase the difficulty of pathologic interpretation. </p><p></p><p class="bulletIndent1">Obtaining a mucosal lesional specimen is not always possible in MMP because affected mucosa is friable and easily erodes. A biopsy for DIF should still be performed in these cases [<a href="#rid87">87</a>]. (See <a class="local">'General principles'</a> above and <a class="local">'Direct immunofluorescence'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Specimen transport</strong> – Specimens obtained for H&amp;E are placed in formalin for processing.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Biopsy interpretation</strong> – Common histopathologic findings in cutaneous lesions of bullous pemphigoid include [<a href="#rid1">1</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Eosinophilic spongiosis (particularly in early lesions)  (<a class="graphic graphic_picture graphicRef79687" href="/z/d/graphic/79687.html" rel="external">picture 6</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Subepidermal blister formation (often with numerous eosinophils within cleft)  (<a class="graphic graphic_picture graphicRef66267" href="/z/d/graphic/66267.html" rel="external">picture 7</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A superficial, dermal, inflammatory cell infiltrate of variable intensity with lymphocytes, eosinophils, and neutrophils  (<a class="graphic graphic_picture graphicRef79687" href="/z/d/graphic/79687.html" rel="external">picture 6</a>) </p><p></p><p class="bulletIndent1">The histopathologic findings in <strong>nonbullous</strong> pemphigoid are often nonspecific. A dermal, perivascular infiltrate with eosinophils is a common finding [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent1">Histopathologic examination of mucosal lesions of MMP shows epithelial-subepithelial cleavage and a mixed, submucosal, inflammatory cell infiltrate composed of lymphocytes, histiocytes, neutrophils, and eosinophils [<a href="#rid45">45</a>]. Additional findings may include plasma cell infiltration and subepidermal fibrosis; the latter is a finding consistent with the scarring nature of MMP [<a href="#rid45">45</a>].</p><p></p><p class="headingAnchor" id="H53290533"><span class="h4">Direct immunofluorescence</span><span class="headingEndMark"> — </span>Direct immunofluorescence (DIF) is a highly sensitive, supportive diagnostic test for pemphigoid [<a href="#rid35">35,86-88</a>]. The procedure utilizes labeled antibodies to detect immunoglobulin binding and complement deposits in tissue. DIF is a more sensitive test for the diagnosis of bullous pemphigoid and MMP than serum IIF or ELISA tests [<a href="#rid35">35,86,87</a>] (see  <a class="medical medical_review" href="/z/d/html/13684.html" rel="external">"Approach to the patient with cutaneous blisters", section on 'Direct immunofluorescence'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Biopsy technique </strong>– In contrast to biopsy specimens for H&amp;E histopathologic evaluation, biopsy specimens for DIF should be obtained from perilesional, not lesional, skin  (<a class="graphic graphic_table graphicRef57402" href="/z/d/graphic/57402.html" rel="external">table 2</a>). Different definitions have been used for "perilesional" skin, including an erythematous or urticarial area or normal-appearing skin adjacent to (but <strong>not</strong> including) a blister:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cutaneous biopsies</strong> – For cutaneous biopsies, we typically aim to biopsy an erythematous or urticarial area adjacent to a blister [<a href="#rid89">89</a>]. Newly inflamed skin unassociated with a blister is also acceptable in patients with findings suggestive of the prodromal phase of bullous pemphigoid or of nonbullous pemphigoid.</p><p></p><p class="bulletIndent2">Whether biopsying perilesional, inflamed skin is preferred over perilesional, normal-appearing skin is unclear. One prospective study that compared DIF findings in skin taken from erythematous skin adjacent to a blister and normal-appearing skin within 2 cm of an erythematous area in 43 patients with autoimmune blistering disease (including 40 with bullous pemphigoid) did not find a significant difference in DIF findings [<a href="#rid90">90</a>]. </p><p></p><p class="bulletIndent2">Various explanations have been put forth for discordant DIF results, especially with respect to false-negative findings. Increased potential for false-negative findings in distal extremities has been disputed [<a href="#rid91">91-95</a>]. DIF may be a less useful diagnostic test in localized bullous pemphigoid than in generalized disease [<a href="#rid93">93</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mucosal biopsies</strong> – On mucosa, tissue immediately adjacent to an erosion can be friable. A tissue specimen from normal-appearing mucosa several millimeters away from the edge of a lesion can be obtained. Intact mucosa with epithelium attached to subepithelium is optimal for DIF. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Specimen transport</strong> – The tissue specimen for DIF <strong>should not be placed in formalin</strong>. Rather, the specimen should be promptly placed in a transport medium compatible with the performance of immunofluorescence studies, such as Michel's medium or Zeus medium  (<a class="graphic graphic_table graphicRef57402" href="/z/d/graphic/57402.html" rel="external">table 2</a>). Specimens for DIF should be transported promptly to an immunodermatology laboratory for receipt within seven days of obtaining the specimen; transport medium does not preserve a specimen indefinitely. </p><p></p><p class="bulletIndent1">Some immunodermatology laboratories will also accept specimens transported on normal, saline-soaked gauze (provided they are received during laboratory working hours within six hours of obtaining them; sooner is better) or specimens that are flash frozen and transported on dry ice  (<a class="graphic graphic_table graphicRef57402" href="/z/d/graphic/57402.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Interpretation</strong> – The classic DIF findings in bullous pemphigoid and MMP include [<a href="#rid45">45,86,88,96</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bullous pemphigoid </strong>–<strong> </strong>Linear IgG and/or linear C3 staining along the basement membrane zone is present in more than 90 percent of cases  (<a class="graphic graphic_picture graphicRef86372 graphicRef86950 graphicRef86951" href="/z/d/graphic/86372.html" rel="external">picture 8A-C</a>). Less intense linear basement membrane zone staining for immunoglobulin M (IgM), immunoglobulin A (IgA), and/or immunoglobulin E (IgE) may be present. Linear IgM with linear C3 is rare [<a href="#rid97">97</a>]. DIF is less likely to be characteristically positive in nonbullous pemphigoid, supporting performance of both DIF and serologic studies [<a href="#rid34">34,35</a>]. (See <a class="local">'Test selection'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mucous membrane pemphigoid </strong>– Linear IgG, linear IgA, and/or linear C3 staining along the basement membrane zone is detected in approximately 70 to 100 percent of cases. Repeat DIF testing on more than one biopsy specimen may be of value for patients with suspected MMP who test negative; multiple or repeated biopsies increase the sensitivity of DIF for the diagnosis of MMP  (<a class="graphic graphic_algorithm graphicRef120171" href="/z/d/graphic/120171.html" rel="external">algorithm 1</a>) [<a href="#rid98">98</a>]. Linear IgE basement membrane zone staining can be detected in specimens from some patients [<a href="#rid99">99</a>].</p><p></p><p class="bulletIndent1">Additional clues for diagnosis may be provided by analysis of the linear pattern of basement membrane zone antibody staining detected in DIF. Whereas an n-serrated pattern has been associated with bullous pemphigoid, MMP, anti-p200 pemphigoid, and linear IgA dermatosis  (<a class="graphic graphic_picture graphicRef86951" href="/z/d/graphic/86951.html" rel="external">picture 8C</a>), a u-serrated pattern has been described in epidermolysis bullosa acquisita and bullous systemic lupus erythematosus  (<a class="graphic graphic_picture graphicRef86952" href="/z/d/graphic/86952.html" rel="external">picture 9</a>) [<a href="#rid100">100,101</a>]. A true linear pattern is commonly observed along with the characteristic n-serrated and u-serrated patterns in all of these immunobullous diseases [<a href="#rid100">100,101</a>].</p><p></p><p class="bulletIndent1">A modified DIF technique has been described utilizing basement membrane zone-split perilesional skin or mucosa from patients with suspected pemphigoid. Theoretically, this allows for more precise localization of antibody binding within the epithelial basement membrane zone of diseased tissue and, therefore, additional information for diagnosis [<a href="#rid102">102</a>]. However, the accuracy and reliability of this technically difficult testing procedure have not been established. In particular, basement membrane zone separation is often difficult and may be variable with inflamed skin and frequently is impossible to perform on mucosal specimens. Performing IIF with the patient's serum on basement membrane zone-split skin substrate is a more practical test. (See <a class="local">'Indirect immunofluorescence assay'</a> below.)</p><p></p><p class="headingAnchor" id="H3313815639"><span class="h3">Serum tests</span><span class="headingEndMark"> — </span>IIF and ELISA testing can support a diagnosis of bullous pemphigoid or MMP. (See <a class="local">'Test selection'</a> above.)</p><p class="headingAnchor" id="H53290540"><span class="h4">Indirect immunofluorescence assay</span><span class="headingEndMark"> — </span>Indirect immunofluorescence (IIF) testing is used to detect circulating basement membrane zone antibodies  (<a class="graphic graphic_picture graphicRef82836" href="/z/d/graphic/82836.html" rel="external">picture 10A</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Technique</strong> – To perform this test, the patient's serum is overlaid on an epithelial tissue substrate, incubated, and then stained for fluorescent detection of antibodies  (<a class="graphic graphic_table graphicRef57402" href="/z/d/graphic/57402.html" rel="external">table 2</a>). Typically, both monkey esophagus and human skin that is artificially split at the level of the lower lamina lucida of the basement membrane zone are utilized. The human skin is split using prolonged exposure (48 to 72 hours) to 1 M sodium chloride (salt-split skin) or short exposure (30 minutes) to ethylenediaminetetraacetic acid (EDTA). (See  <a class="medical medical_review" href="/z/d/html/13684.html" rel="external">"Approach to the patient with cutaneous blisters", section on 'Indirect immunofluorescence'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Interpretation</strong> – IIF findings supportive of bullous pemphigoid or MMP consist of IgG antibody localization along the basement membrane zone. The location of antibody deposition on basement membrane zone-split skin provides information that may be helpful for distinguishing bullous pemphigoid from other autoimmune skin diseases and for identifying patients with MMP at risk for malignancy-associated anti-laminin 332 MMP:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Role in distinguishing autoimmune blistering diseases</strong> – Monkey esophagus is a useful substrate because it can broadly categorize autoimmune diseases based on antibody staining patterns. </p><p></p><p class="bulletIndent2">IIF with a basement membrane zone-split skin substrate aids in distinguishing among certain subepithelial immunobullous diseases because the test allows for localization of antibody deposition within the basement membrane zone. Specimens from patients with <strong>bullous pemphigoid typically demonstrate antibody localized to the epidermal side (roof) of basement membrane zone-split skin</strong>, whereas in specimens from patients with epidermolysis bullosa acquisita, bullous lupus erythematosus, anti-laminin 332 pemphigoid, and anti-p200 (laminin gamma-1) pemphigoid, antibodies typically localize to the dermal side  (<a class="graphic graphic_picture graphicRef82836 graphicRef86374" href="/z/d/graphic/82836.html" rel="external">picture 10A-B</a>).</p><p></p><p class="bulletIndent2">Among the autoimmune subepithelial immunobullous diseases, anti-p200 pemphigoid may be the most common cause of antibody deposition on the dermal side of split skin. In a German study of 141 serum specimens demonstrating autoantibody binding to the dermal side of split skin, 115 sera showed reactivity against p200 or laminin gamma-1 [<a href="#rid103">103</a>]. Combined epidermal-dermal staining patterns on basement membrane zone-split skin may be occasionally found in bullous pemphigoid and bullous lupus erythematosus  (<a class="graphic graphic_picture graphicRef87135" href="/z/d/graphic/87135.html" rel="external">picture 11</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Identification of patients at risk for laminin 332 pemphigoid</strong> – In MMP, basement membrane zone-split skin IIF is particularly useful for recognizing patients at risk for malignancy-associated laminin 332 MMP. In this condition, antibodies are found along the dermal side of the split [<a href="#rid104">104,105</a>].</p><p></p><p class="bulletIndent2">Specific testing to confirm a diagnosis of anti-laminin 332 MMP remains limited to specialized centers and research settings [<a href="#rid106">106</a>]. Additional studies are needed to validate detection of antibodies with an IIF assay to recombinant laminin 332 [<a href="#rid107">107</a>]. (See <a class="local">'Malignancy'</a> above and <a class="local">'Differential diagnosis'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Diagnostic value</strong> – IIF is a highly specific test for bullous pemphigoid [<a href="#rid35">35,86</a>]. In a retrospective study in which 313 patients with bullous pemphigoid were compared with 488 controls, the specificities of IIF on rabbit esophagus, IIF on monkey esophagus, and IIF on human salt-split skin for diagnosis were 96.5, 97.1, and 100 percent, respectively [<a href="#rid86">86</a>]. The sensitivities of these tests for diagnosis were 73.2, 73.3, and 72 percent, respectively. DIF had a similar specificity but was more sensitive. The specificity of DIF was 98 percent, and the sensitivity of DIF was 90.8 percent.</p><p></p><p class="bulletIndent2">In early studies of MMP, IIF was positive in fewer than one-third of patients [<a href="#rid45">45</a>]. However, the use of human basement membrane zone-split skin and/or concentrated serum may increase the likelihood of detecting circulating antibodies [<a href="#rid45">45,108,109</a>]. In one series of eight patients with MMP, IIF on basement membrane zone-split skin was positive in 50 percent [<a href="#rid108">108</a>]. A larger series of 67 patients found that IIF on a basement membrane zone-split skin substrate yielded positive antibodies in 84 percent of patients [<a href="#rid109">109</a>].</p><p></p><p class="headingAnchor" id="H53290547"><span class="h4">Enzyme-linked immunosorbent assay</span><span class="headingEndMark"> — </span>The identification of increased circulating IgG antibodies against BP180 and BP230 in patients with bullous pemphigoid and MMP has led to the use of adjunctive, antigen-specific serologic testing for these basement membrane zone antigens in the diagnosis of these disorders  (<a class="graphic graphic_figure graphicRef67891" href="/z/d/graphic/67891.html" rel="external">figure 1</a>). The most common technique used for this purpose is enzyme-linked immunosorbent assay (ELISA) (see  <a class="medical medical_review" href="/z/d/html/16864.html" rel="external">"Epidemiology and pathogenesis of bullous pemphigoid and mucous membrane pemphigoid", section on 'Bullous pemphigoid'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Technique</strong> – ELISAs for bullous pemphigoid antibodies are commercially available. This testing detects circulating IgG that reacts with type XVII collagen or BP180 (specifically, the NC16A domain of BP180, which is the most common antigenic target, also known as bullous pemphigoid antigen 2 [BPAg2]) and with BP230 (specifically, fused antigenic targets from the N-terminal domain, central rod domain, and C-terminal domain of human BP230 and that is also known as bullous pemphigoid antigen 1 [BPAg1]).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Interpretation</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bullous pemphigoid</strong> – ELISA for antibodies to the BP180 NC16A domain is useful for baseline information in the diagnosis of bullous pemphigoid. Studies have documented sensitivity and specificity of 72 to 90 percent and 90 to 99 percent, respectively [<a href="#rid86">86,110-112</a>]. Since IgG BP180 NC16A antibody levels also correlate with disease activity [<a href="#rid113">113</a>], many clinicians (including ourselves) utilize ELISA testing, not only to support the diagnosis of bullous pemphigoid but also as a measure of the response to therapy. (See  <a class="medical medical_review" href="/z/d/html/15297.html" rel="external">"Management and prognosis of bullous pemphigoid", section on 'Assessing response to therapy'</a>.)</p><p></p><p class="bulletIndent2">ELISA for BP230 antibodies is less likely to be positive in bullous pemphigoid than ELISA testing for BP180 antibodies [<a href="#rid86">86,110,114</a>]. In a retrospective study that evaluated ELISA results in 190 patients with bullous pemphigoid, the sensitivity and specificity of the assay for BP230 were 61 and 96 percent, respectively, compared with 79 and 90 percent, respectively, for BP180 [<a href="#rid110">110</a>]. Moreover, combined testing for BP180 and BP230 antibodies was only slightly more sensitive than BP180 alone; the sensitivity and specificity of conjoint testing were 87 and 88 percent, respectively. Although this finding suggests that testing for BP230 should be reserved for patients who test negatively for BP180, immunodermatology laboratories, including ours, test for antibodies to both antigens in diagnostic panels for bullous pemphigoid [<a href="#rid110">110</a>]. We have observed a subset of pemphigoid patients who have strong epidermal pattern basement membrane zone IgG antibodies by IIF and relatively high levels of IgG BP230 antibodies by ELISA but normal IgG BP180 antibody levels. (See  <a class="medical medical_review" href="/z/d/html/16864.html" rel="external">"Epidemiology and pathogenesis of bullous pemphigoid and mucous membrane pemphigoid", section on 'Pathogenesis'</a>.)</p><p></p><p class="bulletIndent2">Patients with bullous pemphigoid in whom BP180 and BP230 ELISA testing is negative may have antibodies to epitopes of BP180 or BP230 that are not recognized by commercial ELISA tests or may have antibodies to basement membrane zone antigens other than BP180 and BP230. In support of this observation, a study of 51 patients with clinical, histopathologic, and DIF findings consistent with bullous pemphigoid identified four patients (8 percent) in whom ELISA for BP180 NC16A was negative, three of whom also had negative ELISA for BP230 [<a href="#rid115">115</a>]. Despite the negative ELISA for BP180, further analysis by immunoblot revealed strong reactivity to BP180 epitopes outside of NC16A in all four patients, and IIF on basement membrane zone-split skin was positive in three of the four ELISA BP180-negative patients. A negative ELISA for BP180 NC16A domain in bullous pemphigoid may be associated with milder clinical manifestations [<a href="#rid116">116</a>].</p><p></p><p class="bulletIndent2">The detection of BP180 and/or BP230 antibodies in serum does not definitively confirm a diagnosis of bullous pemphigoid. Correlation of ELISA findings with IIF and/or DIF is necessary for reducing the risk for misdiagnosing the disease, as demonstrated in a study that assessed overlap in positivity of DIF, IIF, ELISA, and immunoblotting in patients with bullous pemphigoid [<a href="#rid35">35</a>]. In one series of 337 people without bullous pemphigoid, 25 (7 percent) tested positively for one or both BP180 and BP230 autoantibodies via ELISA [<a href="#rid117">117</a>]. In another series at the same institution, 208 patients with BP180 or BP230 antibodies detected via ELISA and negative DIF for pemphigoid were assigned a wide variety of clinical diagnoses, including dermatitis as the most common diagnosis (72 patients [35 percent]) [<a href="#rid118">118</a>]. Bullous pemphigoid was the working clinical diagnosis in only 20 patients (10 percent) based upon review of the clinical presentation, positive IIF test results, and increased BP180 and BP230 antibody levels.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mucous membrane pemphigoid</strong> – MMP may present with autoantibodies directed against a variety of antigens, including BP180, BP230, laminin 332 (previously known as epiligrin and laminin 5), alpha-6 beta-4 integrin, and type VII collagen  (<a class="graphic graphic_figure graphicRef67891" href="/z/d/graphic/67891.html" rel="external">figure 1</a>) [<a href="#rid43">43,119-123</a>]. Limited sensitivity of ELISA testing for BP180 and BP230 antibodies in the diagnosis of MMP prevents the sole use of such testing.</p><p></p><p class="bulletIndent2">The reliability of ELISA testing may differ among patients with MMP. Pooled data analysis in a systematic review of studies reporting autoantibody profiles of patients with MMP who had positive immunoblot or immunoprecipitation to the NC16A domain of BP180 found the sensitivity and specificity of ELISA using both NC16A and C-terminal epitope portions of BP180 to be 73 and 94 percent, respectively [<a href="#rid123">123</a>]. However, among patients with IgG reactivity against the C-terminal domain of BP180 on immunoblot or immunoprecipitation, the sensitivity and specificity of ELISA testing were 43 and 56 percent, respectively.</p><p></p><p class="bulletIndent2">Antigen-specific testing of serum for basement membrane zone antibodies other than BP180 and BP230 is primarily performed in research laboratories, limiting the value of this testing mode in the MMP population. However, additional tests may be available in the future. Additional studies are necessary to confirm the findings of a retrospective study of 154 patients with MMP that associated the detection of laminin 332 antibodies via a novel ELISA with a greater likelihood for severe disease [<a href="#rid119">119</a>]. Further study is also necessary to clarify whether the detection of salivary IgA and IgG antibodies to BP180 NC16A by ELISA is a useful diagnostic biomarker for MMP [<a href="#rid124">124</a>]. (See  <a class="medical medical_review" href="/z/d/html/16864.html" rel="external">"Epidemiology and pathogenesis of bullous pemphigoid and mucous membrane pemphigoid", section on 'Mucous membrane pemphigoid'</a>.)</p><p></p><p class="headingAnchor" id="H1675218423"><span class="h4">Other tests</span><span class="headingEndMark"> — </span>Other techniques that have been utilized for the detection of antibodies in bullous pemphigoid include immunoblotting and immunoprecipitation. However, these tests are technically demanding and generally are not utilized in the clinical setting [<a href="#rid1">1,85</a>].</p><p class="headingAnchor" id="H588056"><span class="h1">OTHER LABORATORY FINDINGS</span><span class="headingEndMark"> — </span>Peripheral blood eosinophilia is common in patients with bullous pemphigoid but is not a diagnostic finding [<a href="#rid125">125,126</a>]. Increased interleukin (IL) 5, a critical Th2 cytokine in eosinophil production and activation, has been observed in peripheral blood and blister fluid in patients with bullous pemphigoid but has not been systematically studied [<a href="#rid127">127,128</a>]. Increased serum IgE levels are also commonly found [<a href="#rid129">129,130</a>].</p><p class="headingAnchor" id="H20007021"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The clinical findings in bullous pemphigoid and MMP may resemble a variety of other diseases, including other variants of pemphigoid and additional blistering or nonblistering diseases  (<a class="graphic graphic_table graphicRef69192" href="/z/d/graphic/69192.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H12467777"><span class="h2">Other pemphigoid variants</span><span class="headingEndMark"> — </span>Examples of pemphigoid variants in the differential diagnosis of bullous pemphigoid and MMP include pemphigoid gestationis, anti-p200 pemphigoid, and Brunsting-Perry pemphigoid.</p><p class="headingAnchor" id="H12467836"><span class="h3">Pemphigoid gestationis</span><span class="headingEndMark"> — </span>Pemphigoid gestationis is an autoimmune subepidermal blistering disorder that develops during pregnancy and the postpartum period. Patients typically develop intensely pruritic papules, urticarial plaques, vesicles, and bullae that begin on the abdomen prior to spreading to other areas [<a href="#rid131">131,132</a>]. The face and mucous membranes are usually spared.</p><p>Like bullous pemphigoid, patients with pemphigoid gestationis have circulating BP180 antibodies that are detected by enzyme-linked immunosorbent assay (ELISA) [<a href="#rid133">133</a>]. On direct immunofluorescence (DIF), complement deposition predominates at the basement membrane zone. Pemphigoid gestationis is discussed in greater detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/5564.html" rel="external">"Dermatoses of pregnancy", section on 'Pemphigoid gestationis'</a>.)</p><p class="headingAnchor" id="H12467889"><span class="h3">Anti-p200 (laminin gamma-1) pemphigoid</span><span class="headingEndMark"> — </span>Anti-p200 pemphigoid, also known as anti-laminin gamma-1 pemphigoid, is a variant of pemphigoid that is characterized by antibodies to a 200 kilodalton (kD) component of the dermal-epidermal junction. Indirect immunofluorescence (IIF) on basement membrane zone-split skin demonstrates dermal localization of basement membrane zone antibodies [<a href="#rid134">134</a>]. The antigenic target, in most cases, is the gamma-1 subunit of laminin 311 (previously known as laminin 6). (See <a class="local">'Indirect immunofluorescence assay'</a> above.)</p><p>Patients with this type of pemphigoid are usually younger than those with bullous pemphigoid but present with similar clinical features. In one series of 29 patients with this disorder, 25 patients were male, and the mean age was 61 years [<a href="#rid135">135</a>]. Additionally, 14 patients had coexistent psoriasis. In another series of 12 patients, tense, acral blisters and mucosal involvement were characteristic clinical features along with pruritus, and no patients had psoriasis [<a href="#rid136">136</a>]. </p><p>Specific testing to confirm the presence of antibodies to p200, or particularly to laminin gamma-1, remains limited to specialized centers and research settings [<a href="#rid137">137</a>]. As a result, it is likely that patients with this form of pemphigoid are erroneously diagnosed with bullous pemphigoid or epidermolysis bullosa acquisita based on DIF findings [<a href="#rid136">136</a>]. Anti-p200 pemphigoid is one of the few diagnoses indicated by IIF testing that detects serum IgG basement membrane zone antibodies bound to the dermal side of split skin substrate; other examples include epidermolysis bullosa acquisita, bullous lupus, and anti-laminin 332 pemphigoid. Techniques that have been used to specifically identify p200 antibodies include immunoblot with human dermal extract, ELISA to laminin gamma-1, IIF on skin substrates deficient in type VII collagen and laminin 332, and localization of collagen type IV to the floor of blistering skin [<a href="#rid136">136,138</a>].</p><p class="headingAnchor" id="H12467264"><span class="h3">Brunsting-Perry pemphigoid</span><span class="headingEndMark"> — </span>Brunsting-Perry pemphigoid is a cicatricial (scarring) form of pemphigoid that most commonly occurs in older males. Affected patients develop subepidermal blisters localized to the head or neck  (<a class="graphic graphic_picture graphicRef54769" href="/z/d/graphic/54769.html" rel="external">picture 12</a>). A variety of basement membrane zone antibodies have been detected in this variant [<a href="#rid139">139-141</a>]. </p><p class="headingAnchor" id="H12467920"><span class="h2">Cutaneous lesions</span><span class="headingEndMark"> — </span>Examples of other disorders in the differential diagnosis for patients with cutaneous lesions include  (<a class="graphic graphic_table graphicRef69192" href="/z/d/graphic/69192.html" rel="external">table 1</a> and <a class="graphic graphic_algorithm graphicRef120171" href="/z/d/graphic/120171.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Urticaria and eczematous dermatitis</strong> – The prodromal-phase lesions of bullous pemphigoid may resemble the erythematous and edematous plaques of urticaria or the erythematous papules or plaques of eczematous dermatitis. Unlike true urticaria, the lesions of bullous pemphigoid are not transient. DIF studies of biopsy specimens are useful for distinguishing both of these disorders from bullous pemphigoid. (See  <a class="medical medical_review" href="/z/d/html/8101.html" rel="external">"New-onset urticaria"</a> and  <a class="medical medical_review" href="/z/d/html/1729.html" rel="external">"Atopic dermatitis (eczema): Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Skin-predominant epidermolysis bullosa acquisita</strong> – Epidermolysis bullosa acquisita is a rare disorder characterized by subepidermal blister formation involving the skin and mucous membranes  (<a class="graphic graphic_picture graphicRef62505" href="/z/d/graphic/62505.html" rel="external">picture 13</a>). Unlike bullous pemphigoid, IIF on basement membrane zone-split skin demonstrates serum antibody bound to the dermal side of the split, and residual scarring and milia are common. Specific ELISA testing for antibodies to type VII collagen is useful for making this diagnosis. (See  <a class="medical medical_review" href="/z/d/html/15299.html" rel="external">"Epidermolysis bullosa acquisita"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pemphigus</strong> – Pemphigus is a group of autoimmune blistering disorders characterized by autoantibodies directed against epithelial cell surface antigens (also known as intercellular substance [ICS] antigens). The flaccid nature of blisters in pemphigus contrasts with the tense, subepidermal bullae in pemphigoid  (<a class="graphic graphic_picture graphicRef53425 graphicRef63170 graphicRef57924" href="/z/d/graphic/53425.html" rel="external">picture 2A-C</a>). DIF studies are essential for diagnosis. Several pemphigus variants exist, including paraneoplastic pemphigus  (<a class="graphic graphic_picture graphicRef59594" href="/z/d/graphic/59594.html" rel="external">picture 2D</a>), which may show basement membrane zone antibodies in addition to cell surface antibodies. (See  <a class="medical medical_review" href="/z/d/html/15305.html" rel="external">"Paraneoplastic pemphigus"</a> and  <a class="medical medical_review" href="/z/d/html/83684.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of pemphigus"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Linear IgA disease</strong> – Linear IgA disease, which includes linear IgA bullous dermatosis and chronic bullous disease of childhood, is an autoimmune subepithelial blistering disorder that usually presents with annular and grouped, tense vesicles arising on inflamed skin  (<a class="graphic graphic_picture graphicRef56434" href="/z/d/graphic/56434.html" rel="external">picture 14</a>). The skin lesions are often described as resembling a cluster of jewels. Mucosal sites may also be affected. The DIF finding of linear IgA antibody staining at the basement membrane zone in a perilesional skin biopsy specimen is essential for this diagnosis. (See  <a class="medical medical_review" href="/z/d/html/15301.html" rel="external">"Linear IgA bullous dermatosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dermatitis herpetiformis</strong> – Intensely pruritic, inflammatory papules, vesicles, or crusts with a predilection for the elbows, knees, and buttocks are characteristic of dermatitis herpetiformis, another autoimmune subepidermal blistering disorder  (<a class="graphic graphic_picture graphicRef78315" href="/z/d/graphic/78315.html" rel="external">picture 15</a>). The histopathologic finding of neutrophilic microabscesses in dermal papillary tips by hematoxylin and eosin (H&amp;E) and the immunohistopathologic detection of granular and/or fibrillar IgA deposits in the papillary dermis by DIF are consistent with this diagnosis. (See  <a class="medical medical_review" href="/z/d/html/15307.html" rel="external">"Dermatitis herpetiformis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bullous lupus erythematosus</strong> – Bullous systemic lupus erythematosus is a rare disorder. The development of subepidermal blisters with neutrophilic infiltrates in a patient with systemic lupus erythematosus suggests this disease. (See  <a class="medical medical_review" href="/z/d/html/4666.html" rel="external">"Overview of cutaneous lupus erythematosus", section on 'Bullous cutaneous lupus erythematosus'</a>.)</p><p></p><p class="headingAnchor" id="H588016"><span class="h2">Mucosal lesions</span><span class="headingEndMark"> — </span>Examples of other causes of mucosal erosions that must be distinguished from those associated with MMP and bullous pemphigoid include pemphigus variants  (<a class="graphic graphic_picture graphicRef57924 graphicRef59594" href="/z/d/graphic/57924.html" rel="external">picture 2C-D</a>), linear IgA bullous dermatosis or epidermolysis bullosa acquisita with mucosal involvement, oral and genital mucosal lichen planus  (<a class="graphic graphic_picture graphicRef54143 graphicRef60224" href="/z/d/graphic/54143.html" rel="external">picture 16A-B</a>), erythema multiforme  (<a class="graphic graphic_picture graphicRef68153 graphicRef58969" href="/z/d/graphic/68153.html" rel="external">picture 17A-B</a>), Stevens-Johnson syndrome  (<a class="graphic graphic_picture graphicRef73805" href="/z/d/graphic/73805.html" rel="external">picture 18</a>), HIV-associated mucosal lesions, Behçet syndrome, and aphthous ulcers  (<a class="graphic graphic_picture graphicRef63475" href="/z/d/graphic/63475.html" rel="external">picture 19</a>) [<a href="#rid43">43</a>]. (See  <a class="medical medical_review" href="/z/d/html/15305.html" rel="external">"Paraneoplastic pemphigus"</a> and  <a class="medical medical_review" href="/z/d/html/15301.html" rel="external">"Linear IgA bullous dermatosis"</a> and  <a class="medical medical_review" href="/z/d/html/15299.html" rel="external">"Epidermolysis bullosa acquisita"</a> and  <a class="medical medical_review" href="/z/d/html/15285.html" rel="external">"Oral lichen planus: Pathogenesis, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/5559.html" rel="external">"Erythema multiforme: Pathogenesis, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/2091.html" rel="external">"Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/8223.html" rel="external">"Clinical manifestations and diagnosis of Behçet syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/5572.html" rel="external">"Oral lesions", section on 'Erosive, ulcerative, and bullous lesions'</a> and  <a class="medical medical_review" href="/z/d/html/83684.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of pemphigus"</a>.)</p><p>A broader differential diagnosis for oral or vulvar erosions, ulcers, and bullae is reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5572.html" rel="external">"Oral lesions", section on 'Erosive, ulcerative, and bullous lesions'</a> and  <a class="medical medical_review" href="/z/d/html/5412.html" rel="external">"Vulvar lesions: Differential diagnosis of vesicles, bullae, erosions, and ulcers"</a>.)</p><p>The differential diagnosis for ocular involvement is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/15590.html" rel="external">"Ocular cicatricial pemphigoid", section on 'Differential diagnosis'</a>.)</p><p class="headingAnchor" id="H1191034377"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/121560.html" rel="external">"Society guideline links: Bullous pemphigoid"</a>.)</p><p class="headingAnchor" id="H785956"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Bullous pemphigoid and mucous membrane pemphigoid (MMP) are uncommon autoimmune subepithelial blistering disorders that affect skin and mucous membranes. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Features of bullous pemphigoid</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The onset of blistering lesions in bullous pemphigoid is frequently preceded by a prodromal phase characterized by pruritic, inflammatory plaques that resemble eczematous dermatitis or urticaria. Once the bullous phase develops, patients exhibit multiple tense, 1 to 3 cm bullae as well as erosions and crusts at sites of ruptured bullae  (<a class="graphic graphic_picture graphicRef54541 graphicRef70352 graphicRef79112 graphicRef80385 graphicRef78910 graphicRef72866 graphicRef59590 graphicRef71249 graphicRef50357 graphicRef58359" href="/z/d/graphic/54541.html" rel="external">picture 1A-C, 1G-J, 3A-C</a>). The lesions of bullous pemphigoid usually heal without scarring. Nonblistering forms of bullous pemphigoid can occur. (See <a class="local">'Clinical features of bullous pemphigoid'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The trunk and extremities are typically involved in bullous pemphigoid; localized presentations may also occur. Mucosal disease is present in 10 to 30 percent of patients  (<a class="graphic graphic_picture graphicRef66179" href="/z/d/graphic/66179.html" rel="external">picture 4</a>). (See <a class="local">'Clinical features of bullous pemphigoid'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Features of mucous membrane pemphigoid</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>MMP most commonly presents as desquamative gingivitis or erosions of the oral mucosa. Other potential sites of mucosal involvement include the ocular conjunctiva, skin, pharynx, genitalia, nasal mucosa, larynx, anus, and esophagus  (<a class="graphic graphic_picture graphicRef73874 graphicRef52208 graphicRef63997" href="/z/d/graphic/73874.html" rel="external">picture 1D-F</a>). (See <a class="local">'Clinical features of mucous membrane pemphigoid'</a> above and  <a class="medical medical_review" href="/z/d/html/15590.html" rel="external">"Ocular cicatricial pemphigoid", section on 'Clinical manifestations'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Unlike bullous pemphigoid, lesions of MMP tend to scar. Scarring may result in serious functional impairment. (See <a class="local">'Clinical features of mucous membrane pemphigoid'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with the anti-laminin 332 (previously known as anti-laminin 5 or anti-epiligrin) form of MMP may have an increased risk for internal malignancy. An evaluation for associated malignancy should be performed in patients with immunohistopathologic findings that suggest this disorder. Specific testing for antibodies against laminin 332 is not yet widely available. (See <a class="local">'Malignancy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The evaluation of patients with clinical findings suggestive of bullous pemphigoid or MMP begins with obtaining skin or mucous membrane biopsy specimens from both lesional tissue for hematoxylin and eosin (H&amp;E; light microscopic histopathology) and perilesional tissue for direct immunofluorescence (DIF)  (<a class="graphic graphic_algorithm graphicRef120171" href="/z/d/graphic/120171.html" rel="external">algorithm 1</a>). DIF is highly sensitive for the diagnosis and demonstrates characteristic linear basement membrane zone antibody localization in almost all patients with bullous pemphigoid and the majority of patients with MMP  (<a class="graphic graphic_picture graphicRef86372 graphicRef86950 graphicRef86951" href="/z/d/graphic/86372.html" rel="external">picture 8A-C</a>). (See <a class="local">'Tissue biopsy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Serologic studies to detect circulating basement membrane zone antibodies by indirect immunofluorescence (IIF) and enzyme-linked immunosorbent assay (ELISA) are also useful for the diagnosis of bullous pemphigoid and MMP. Both DIF and serologic studies should be performed as part of the diagnostic evaluation  (<a class="graphic graphic_picture graphicRef82836" href="/z/d/graphic/82836.html" rel="external">picture 10A</a> and <a class="graphic graphic_algorithm graphicRef120171" href="/z/d/graphic/120171.html" rel="external">algorithm 1</a>). (See <a class="local">'Indirect immunofluorescence assay'</a> above and <a class="local">'Enzyme-linked immunosorbent assay'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The differential diagnosis of bullous pemphigoid and MMP is broad  (<a class="graphic graphic_table graphicRef69192" href="/z/d/graphic/69192.html" rel="external">table 1</a>). The possibility of other pemphigoid disorders, other blistering disorders, and nonbullous diseases must be considered. (See <a class="local">'Differential diagnosis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Schmidt E, della Torre R, Borradori L. Clinical features and practical diagnosis of bullous pemphigoid. Dermatol Clin 2011; 29:427.</a></li><li><a class="nounderline abstract_t">Bernard P, Antonicelli F. Bullous Pemphigoid: A Review of its Diagnosis, Associations and Treatment. Am J Clin Dermatol 2017; 18:513.</a></li><li><a class="nounderline abstract_t">Kasperkiewicz M, Zillikens D, Schmidt E. Pemphigoid diseases: pathogenesis, diagnosis, and treatment. Autoimmunity 2012; 45:55.</a></li><li><a class="nounderline abstract_t">Montagnon CM, Tolkachjov SN, Murrell DF, et al. Subepithelial autoimmune blistering dermatoses: Clinical features and diagnosis. J Am Acad Dermatol 2021; 85:1.</a></li><li><a class="nounderline abstract_t">Di Zenzo G, Marazza G, Borradori L. Bullous pemphigoid: physiopathology, clinical features and management. Adv Dermatol 2007; 23:257.</a></li><li><a class="nounderline abstract_t">Uzun S, Durdu M. The specificity and sensitivity of Nikolskiy sign in the diagnosis of pemphigus. J Am Acad Dermatol 2006; 54:411.</a></li><li><a class="nounderline abstract_t">Kershenovich R, Hodak E, Mimouni D. Diagnosis and classification of pemphigus and bullous pemphigoid. Autoimmun Rev 2014; 13:477.</a></li><li><a class="nounderline abstract_t">Baum S, Sakka N, Artsi O, et al. Diagnosis and classification of autoimmune blistering diseases. Autoimmun Rev 2014; 13:482.</a></li><li><a class="nounderline abstract_t">Hashimoto T, Kursewicz CD, Fayne RA, et al. Pathophysiologic mechanisms of itch in bullous pemphigoid. J Am Acad Dermatol 2020; 83:53.</a></li><li><a class="nounderline abstract_t">Yancey KB, Egan CA. Pemphigoid: clinical, histologic, immunopathologic, and therapeutic considerations. JAMA 2000; 284:350.</a></li><li><a class="nounderline abstract_t">Kridin K, Bergman R. Assessment of the Prevalence of Mucosal Involvement in Bullous Pemphigoid. JAMA Dermatol 2019; 155:166.</a></li><li><a class="nounderline abstract_t">Benmously-Mlika R, Hammami-Ghorbel H, Mokhtar I. Onychomadesis during bullous pemphigoid. J Am Acad Dermatol 2013; 69:e306.</a></li><li><a class="nounderline abstract_t">Tosti A, André M, Murrell DF. Nail involvement in autoimmune bullous disorders. Dermatol Clin 2011; 29:511.</a></li><li><a class="nounderline abstract_t">Tran JT, Mutasim DF. Localized bullous pemphigoid: a commonly delayed diagnosis. Int J Dermatol 2005; 44:942.</a></li><li><a class="nounderline abstract_t">Borradori L, Prost C, Wolkenstein P, et al. Localized pretibial pemphigoid and pemphigoid nodularis. J Am Acad Dermatol 1992; 27:863.</a></li><li><a class="nounderline abstract_t">Kitajima Y, Suzuki M, Johkura Y, Yaoita H. Localized bullous pemphigoid: report of a case with an immunofluorescence and electron microscopical studies on the lesional distribution of 180-KD bullous pemphigoid antigen, beta 4 integrin, and type VII collagen. J Dermatol 1993; 20:406.</a></li><li><a class="nounderline abstract_t">Kakurai M, Demitsu T, Azuma R, et al. Localized pemphigoid (pretibial type) with IgG antibody to BP180 NC16a domain successfully treated with minocycline and topical corticosteroid. Clin Exp Dermatol 2007; 32:759.</a></li><li><a class="nounderline abstract_t">Kohroh K, Suga Y, Mizuno Y, et al. Case of localized bullous pemphigoid with unique clinical manifestations in the lower legs. J Dermatol 2007; 34:482.</a></li><li><a class="nounderline abstract_t">Urano S. Localized bullous pemphigoid of the vulva. J Dermatol 1996; 23:580.</a></li><li><a class="nounderline abstract_t">Saad RW, Domloge-Hultsch N, Yancey KB, et al. Childhood localized vulvar pemphigoid is a true variant of bullous pemphigoid. Arch Dermatol 1992; 128:807.</a></li><li><a class="nounderline abstract_t">Batalla A, Peón G, De la Torre C. Localized bullous pemphigoid at urostomy site. Indian J Dermatol Venereol Leprol 2011; 77:625.</a></li><li><a class="nounderline abstract_t">Vande Maele DM, Reilly JC. Bullous pemphigoid at colostomy site: report of a case. Dis Colon Rectum 1997; 40:370.</a></li><li><a class="nounderline abstract_t">Sheerin N, Bourke JF, Holder J, et al. Bullous pemphigoid following radiotherapy. Clin Exp Dermatol 1995; 20:80.</a></li><li><a class="nounderline abstract_t">Mul VE, van Geest AJ, Pijls-Johannesma MC, et al. Radiation-induced bullous pemphigoid: a systematic review of an unusual radiation side effect. Radiother Oncol 2007; 82:5.</a></li><li><a class="nounderline abstract_t">Quartey-Papafio CM, Hudson PM. Bullous pemphigoid initially localized to sites of burns (scalds) in a patient on sulphasalazine for ulcerative colitis. Clin Exp Dermatol 1994; 19:281.</a></li><li><a class="nounderline abstract_t">Macfarlane AW, Verbov JL. Trauma-induced bullous pemphigoid. Clin Exp Dermatol 1989; 14:245.</a></li><li><a class="nounderline abstract_t">Salomon RJ, Briggaman RA, Wernikoff SY, Kayne AL. Localized bullous pemphigoid. A mimic of acute contact dermatitis. Arch Dermatol 1987; 123:389.</a></li><li><a class="nounderline abstract_t">de la Fuente S, Hernández-Martín Á, de Lucas R, et al. Postvaccination bullous pemphigoid in infancy: report of three new cases and literature review. Pediatr Dermatol 2013; 30:741.</a></li><li><a class="nounderline abstract_t">Nguyen T, Kwan JM, Ahmed AR. Relationship between radiation therapy and bullous pemphigoid. Dermatology 2014; 229:88.</a></li><li><a class="nounderline abstract_t">Kaplan RP. Cutaneous involvement in localized forms of bullous pemphigoid. Clin Dermatol 1987; 5:43.</a></li><li><a class="nounderline abstract_t">Bakker CV, Terra JB, Pas HH, Jonkman MF. Bullous pemphigoid as pruritus in the elderly: a common presentation. JAMA Dermatol 2013; 149:950.</a></li><li class="breakAll">Alonso-Llamazares J, Peters MS, Leiferman KM. Bullous pemphigoid. In: Atlas of Bullous Disease, Jordon RE (Ed), Churchill Livingstone, 2000. p.43.</li><li><a class="nounderline abstract_t">Zhang W, Liu Y, Li C. Generalised nodules in pemphigoid nodularis. Lancet 2017; 389:1930.</a></li><li><a class="nounderline abstract_t">Lamberts A, Meijer JM, Pas HH, et al. Nonbullous pemphigoid: Insights in clinical and diagnostic findings, treatment responses, and prognosis. J Am Acad Dermatol 2019; 81:355.</a></li><li><a class="nounderline abstract_t">Meijer JM, Diercks GFH, de Lang EWG, et al. Assessment of Diagnostic Strategy for Early Recognition of Bullous and Nonbullous Variants of Pemphigoid. JAMA Dermatol 2019; 155:158.</a></li><li><a class="nounderline abstract_t">Zillikens D, Caux F, Mascaro JM, et al. Autoantibodies in lichen planus pemphigoides react with a novel epitope within the C-terminal NC16A domain of BP180. J Invest Dermatol 1999; 113:117.</a></li><li><a class="nounderline abstract_t">Kim J, Chavel S, Girardi M, McNiff JM. Pemphigoid vegetans: a case report and review of the literature. J Cutan Pathol 2008; 35:1144.</a></li><li><a class="nounderline abstract_t">Chan LS, Dorman MA, Agha A, et al. Pemphigoid vegetans represents a bullous pemphigoid variant. Patient's IgG autoantibodies identify the major bullous pemphigoid antigen. J Am Acad Dermatol 1993; 28:331.</a></li><li><a class="nounderline abstract_t">Kim YJ, Kim MY, Kim HO, Park YM. Dyshidrosiform bullous pemphigoid. Acta Derm Venereol 2004; 84:253.</a></li><li><a class="nounderline abstract_t">Cohen PR. Dyshidrosiform Bullous Pemphigoid. Medicina (Kaunas) 2021; 57.</a></li><li><a class="nounderline abstract_t">Lai FJ, Sheu HM, Lee JY, et al. Vesicular pemphigoid with circulating autoantibodies against 230-kDa and 180-kDa proteins, and additional autoantibodies against 97-kDa and 45-kDa proteins. Int J Dermatol 2007; 46:206.</a></li><li><a class="nounderline abstract_t">Duretz C, Antonicelli F, Muller C, et al. Association of Transient Palmoplantar Keratoderma With Clinical and Immunologic Characteristics of Bullous Pemphigoid. JAMA Dermatol 2019; 155:216.</a></li><li><a class="nounderline abstract_t">Chan LS, Ahmed AR, Anhalt GJ, et al. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol 2002; 138:370.</a></li><li><a class="nounderline abstract_t">Ahmed AR, Hombal SM. Cicatricial pemphigoid. Int J Dermatol 1986; 25:90.</a></li><li><a class="nounderline abstract_t">Fleming TE, Korman NJ. Cicatricial pemphigoid. J Am Acad Dermatol 2000; 43:571.</a></li><li><a class="nounderline abstract_t">Sim B, Fook-Chong S, Phoon YW, et al. Multimorbidity in bullous pemphigoid: a case-control analysis of bullous pemphigoid patients with age- and gender-matched controls. J Eur Acad Dermatol Venereol 2017; 31:1709.</a></li><li><a class="nounderline abstract_t">Ren Z, Hsu DY, Brieva J, et al. Hospitalization, inpatient burden and comorbidities associated with bullous pemphigoid in the U.S.A. Br J Dermatol 2017; 176:87.</a></li><li><a class="nounderline abstract_t">Bech R, Kibsgaard L, Vestergaard C. Comorbidities and Treatment Strategies in Bullous Pemphigoid: An Appraisal of the Existing Litterature. Front Med (Lausanne) 2018; 5:238.</a></li><li><a class="nounderline abstract_t">Kibsgaard L, Bay B, Deleuran M, Vestergaard C. A retrospective consecutive case-series study on the effect of systemic treatment, length of admission time, and co-morbidities in 98 bullous pemphigoid patients admitted to a tertiary centre. Acta Derm Venereol 2015; 95:307.</a></li><li><a class="nounderline abstract_t">Marzano AV, Tedeschi A, Polloni I, et al. Prothrombotic state and impaired fibrinolysis in bullous pemphigoid, the most frequent autoimmune blistering disease. Clin Exp Immunol 2013; 171:76.</a></li><li><a class="nounderline abstract_t">Cugno M, Marzano AV, Bucciarelli P, et al. Increased risk of venous thromboembolism in patients with bullous pemphigoid. The INVENTEP (INcidence of VENous ThromboEmbolism in bullous Pemphigoid) study. Thromb Haemost 2016; 115:193.</a></li><li><a class="nounderline abstract_t">Kridin K, Ludwig RJ, Tzur Bitan D, Cohen AD. A History of Asthma Increases the Risk of Bullous Pemphigoid: Insights from a Large Population-Based Study. Dermatology 2021; 237:921.</a></li><li><a class="nounderline abstract_t">Chen CT, Hu HY, Chang YT, et al. Cancer is not a risk factor for bullous pemphigoid: 10-year population-based cohort study. Br J Dermatol 2019; 180:553.</a></li><li><a class="nounderline abstract_t">Foureur N, Descamps V, Lebrun-Vignes B, et al. Bullous pemphigoid in a leg affected with hemiparesia: a possible relation of neurological diseases with bullous pemphigoid? Eur J Dermatol 2001; 11:230.</a></li><li><a class="nounderline abstract_t">Langan SM, Groves RW, West J. The relationship between neurological disease and bullous pemphigoid: a population-based case-control study. J Invest Dermatol 2011; 131:631.</a></li><li><a class="nounderline abstract_t">Bastuji-Garin S, Joly P, Lemordant P, et al. Risk factors for bullous pemphigoid in the elderly: a prospective case-control study. J Invest Dermatol 2011; 131:637.</a></li><li><a class="nounderline abstract_t">Masouyé I, Schmied E, Didierjean L, et al. Bullous pemphigoid and multiple sclerosis: more than a coincidence? Report of three cases. J Am Acad Dermatol 1989; 21:63.</a></li><li><a class="nounderline abstract_t">Kirtschig G, Walkden VM, Venning VA, Wojnarowska F. Bullous pemphigoid and multiple sclerosis: a report of three cases and review of the literature. Clin Exp Dermatol 1995; 20:449.</a></li><li><a class="nounderline abstract_t">Stinco G, Mattighello P, Zanchi M, Patrone P. Multiple sclerosis and bullous pemphigoid: a casual association or a pathogenetic correlation? Eur J Dermatol 2002; 12:186.</a></li><li><a class="nounderline abstract_t">Nielsen NM, Frisch M, Rostgaard K, et al. Autoimmune diseases in patients with multiple sclerosis and their first-degree relatives: a nationwide cohort study in Denmark. Mult Scler 2008; 14:823.</a></li><li><a class="nounderline abstract_t">Gambichler T, Segert H, Höxtermann S, et al. Neurological disorders in patients with bullous pemphigoid: clinical and experimental investigations. J Eur Acad Dermatol Venereol 2015; 29:1758.</a></li><li><a class="nounderline abstract_t">Oh DD, Zhao CY, Murrell DF. A review of case-control studies on the risk factors for the development of autoimmune blistering diseases. J Eur Acad Dermatol Venereol 2016; 30:595.</a></li><li><a class="nounderline abstract_t">Lai YC, Yew YW, Lambert WC. Bullous pemphigoid and its association with neurological diseases: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2016; 30:2007.</a></li><li><a class="nounderline abstract_t">Nakane S, Izumi Y, Oda M, et al. A Potential Link between Amyotrophic Lateral Sclerosis and Bullous Pemphigoid: Six New Cases and a Systematic Review of the Literature. Intern Med 2016; 55:1985.</a></li><li><a class="nounderline abstract_t">Milani-Nejad N, Zhang M, Kaffenberger J. The association between bullous pemphigoid and neurological disorders: a systematic review. Eur J Dermatol 2017; 27:472.</a></li><li><a class="nounderline abstract_t">Langer-Gould A, Albers KB, Van Den Eeden SK, Nelson LM. Autoimmune diseases prior to the diagnosis of multiple sclerosis: a population-based case-control study. Mult Scler 2010; 16:855.</a></li><li><a class="nounderline abstract_t">Wu CY, Hu HY, Chou YJ, et al. Neurological Cancer is a Risk Factor for Bullous Pemphigoid: 11-Year Population-Based Cohort Study. Am J Clin Dermatol 2020; 21:591.</a></li><li><a class="nounderline abstract_t">Bouras C, Riederer BM, Kövari E, et al. Humoral immunity in brain aging and Alzheimer's disease. Brain Res Brain Res Rev 2005; 48:477.</a></li><li><a class="nounderline abstract_t">Chen J, Li L, Chen J, et al. Sera of elderly bullous pemphigoid patients with associated neurological diseases recognize bullous pemphigoid antigens in the human brain. Gerontology 2011; 57:211.</a></li><li><a class="nounderline abstract_t">Li L, Chen J, Wang B, et al. Sera from patients with bullous pemphigoid (BP) associated with neurological diseases recognized BP antigen 1 in the skin and brain. Br J Dermatol 2009; 160:1343.</a></li><li><a class="nounderline abstract_t">Amber KT, Zikry J, Hertl M. A multi-hit hypothesis of bullous pemphigoid and associated neurological disease: Is HLA-DQB1*03:01, a potential link between immune privileged antigen exposure and epitope spreading? HLA 2017; 89:127.</a></li><li><a class="nounderline abstract_t">Ali A, Hu L, Zhao F, et al. BPAG1, a distinctive role in skin and neurological diseases. Semin Cell Dev Biol 2017; 69:34.</a></li><li><a class="nounderline abstract_t">Egan CA, Lazarova Z, Darling TN, et al. Anti-epiligrin cicatricial pemphigoid and relative risk for cancer. Lancet 2001; 357:1850.</a></li><li><a class="nounderline abstract_t">Sadler E, Lazarova Z, Sarasombath P, Yancey KB. A widening perspective regarding the relationship between anti-epiligrin cicatricial pemphigoid and cancer. J Dermatol Sci 2007; 47:1.</a></li><li><a class="nounderline abstract_t">Li X, Qian H, Natsuaki Y, et al. Clinical and immunological findings in 55 patients with anti-laminin 332-type mucous membrane pemphigoid. Br J Dermatol 2021; 185:449.</a></li><li><a class="nounderline abstract_t">La Placa M, Balestri R, Tartari F, et al. Mucous Membrane Pemphigoid-Associated Malignancies: Case Series and a Brief Overview of the Literature. Dermatol Pract Concept 2019; 9:119.</a></li><li><a class="nounderline abstract_t">Miyazaki K. Laminin-5 (laminin-332): Unique biological activity and role in tumor growth and invasion. Cancer Sci 2006; 97:91.</a></li><li><a class="nounderline abstract_t">Ruocco E, Wolf R, Caccavale S, et al. Bullous pemphigoid: associations and management guidelines: facts and controversies. Clin Dermatol 2013; 31:400.</a></li><li><a class="nounderline abstract_t">Cai SC, Allen JC, Lim YL, et al. Association of Bullous Pemphigoid and Malignant Neoplasms. JAMA Dermatol 2015; 151:665.</a></li><li><a class="nounderline abstract_t">Atzmony L, Mimouni I, Reiter O, et al. Association of bullous pemphigoid with malignancy: A systematic review and meta-analysis. J Am Acad Dermatol 2017; 77:691.</a></li><li><a class="nounderline abstract_t">Lucariello RJ, Villablanca SE, Mascaró JM Jr, Reichel M. Association between bullous pemphigoid and malignancy: A meta-analysis. Australas J Dermatol 2018; 59:253.</a></li><li><a class="nounderline abstract_t">Lara-Corrales I, Pope E. Autoimmune blistering diseases in children. Semin Cutan Med Surg 2010; 29:85.</a></li><li><a class="nounderline abstract_t">Fisler RE, Saeb M, Liang MG, et al. Childhood bullous pemphigoid: a clinicopathologic study and review of the literature. Am J Dermatopathol 2003; 25:183.</a></li><li><a class="nounderline abstract_t">Zhao CY, Chiang YZ, Murrell DF. Neonatal Autoimmune Blistering Disease: A Systematic Review. Pediatr Dermatol 2016; 33:367.</a></li><li><a class="nounderline abstract_t">Chan YC, Sun YJ, Ng PP, Tan SH. Comparison of immunofluorescence microscopy, immunoblotting and enzyme-linked immunosorbent assay methods in the laboratory diagnosis of bullous pemphigoid. Clin Exp Dermatol 2003; 28:651.</a></li><li><a class="nounderline abstract_t">Sárdy M, Kostaki D, Varga R, et al. Comparative study of direct and indirect immunofluorescence and of bullous pemphigoid 180 and 230 enzyme-linked immunosorbent assays for diagnosis of bullous pemphigoid. J Am Acad Dermatol 2013; 69:748.</a></li><li><a class="nounderline abstract_t">Rashid H, Meijer JM, Diercks GFH, et al. Assessment of Diagnostic Strategy for Mucous Membrane Pemphigoid. JAMA Dermatol 2021; 157:780.</a></li><li><a class="nounderline abstract_t">Schmidt E, Zillikens D. Modern diagnosis of autoimmune blistering skin diseases. Autoimmun Rev 2010; 10:84.</a></li><li><a class="nounderline abstract_t">Sladden C, Kirchhof MG, Crawford RI. Biopsy location for direct immunofluorescence in patients with suspected bullous pemphigoid impacts probability of a positive test result. J Cutan Med Surg 2014; 18:392.</a></li><li><a class="nounderline abstract_t">Haefliger S, Sitaru S, Cazzaniga S, et al. Diagnostic performance of direct immunofluorescence microscopy studies by biopsy sites in autoimmune subepidermal blistering dermatoses: a prospective study. Br J Dermatol 2020; 183:970.</a></li><li><a class="nounderline abstract_t">Perry DM, Wilson A, Self S, Maize JC. False-Negative Rate of Direct Immunofluorescence on Lower Extremities in Bullous Pemphigoid. Am J Dermatopathol 2021; 43:42.</a></li><li><a class="nounderline abstract_t">Weigand DA. Effect of anatomic region on immunofluorescence diagnosis of bullous pemphigoid. J Am Acad Dermatol 1985; 12:274.</a></li><li><a class="nounderline abstract_t">Weigand DA, Clements MK. Direct immunofluorescence in bullous pemphigoid: effects of extent and location of lesions. J Am Acad Dermatol 1989; 20:437.</a></li><li><a class="nounderline abstract_t">Anstey A, Venning V, Wojnarowska F, et al. Determination of the optimum site for diagnostic biopsy for direct immunofluorescence in bullous pemphigoid. Clin Exp Dermatol 1990; 15:438.</a></li><li><a class="nounderline abstract_t">Fudge JG, Crawford RI. Bullous Pemphigoid: A 10-Year Study of Discordant Results on Direct Immunofluorescence. J Cutan Med Surg 2018; 22:472.</a></li><li class="breakAll">Weedon D. The vesicobullous reaction pattern. In: Weedon's Skin Pathology, 3rd ed, Elsevier, 2010. p.123.</li><li><a class="nounderline abstract_t">Baardman R, Horváth B, Bolling MC, et al. Immunoglobulin M bullous pemphigoid: An enigma. JAAD Case Rep 2020; 6:518.</a></li><li><a class="nounderline abstract_t">Shimanovich I, Nitz JM, Zillikens D. Multiple and repeated sampling increases the sensitivity of direct immunofluorescence testing for the diagnosis of mucous membrane pemphigoid. J Am Acad Dermatol 2017; 77:700.</a></li><li><a class="nounderline abstract_t">Yayli S, Pelivani N, Beltraminelli H, et al. Detection of linear IgE deposits in bullous pemphigoid and mucous membrane pemphigoid: a useful clue for diagnosis. Br J Dermatol 2011; 165:1133.</a></li><li><a class="nounderline abstract_t">Vodegel RM, Jonkman MF, Pas HH, de Jong MC. U-serrated immunodeposition pattern differentiates type VII collagen targeting bullous diseases from other subepidermal bullous autoimmune diseases. Br J Dermatol 2004; 151:112.</a></li><li><a class="nounderline abstract_t">Terra JB, Pas HH, Hertl M, et al. Immunofluorescence serration pattern analysis as a diagnostic criterion in antilaminin-332 mucous membrane pemphigoid: immunopathological findings and clinical experience in 10 Dutch patients. Br J Dermatol 2011; 165:815.</a></li><li><a class="nounderline abstract_t">De A, Rao R, Balachandran C. Salt split technique: a useful tool in the diagnosis of subepidermal bullous disorders. Indian J Dermatol 2010; 55:334.</a></li><li><a class="nounderline abstract_t">Lau I, Goletz S, Holtsche MM, et al. Anti-p200 pemphigoid is the most common pemphigoid disease with serum antibodies against the dermal side by indirect immunofluorescence microscopy on human salt-split skin. J Am Acad Dermatol 2019; 81:1195.</a></li><li><a class="nounderline abstract_t">Domloge-Hultsch N, Anhalt GJ, Gammon WR, et al. Antiepiligrin cicatricial pemphigoid. A subepithelial bullous disorder. Arch Dermatol 1994; 130:1521.</a></li><li><a class="nounderline abstract_t">Domloge-Hultsch N, Gammon WR, Briggaman RA, et al. Epiligrin, the major human keratinocyte integrin ligand, is a target in both an acquired autoimmune and an inherited subepidermal blistering skin disease. J Clin Invest 1992; 90:1628.</a></li><li><a class="nounderline abstract_t">Bekou V, Thoma-Uszynski S, Wendler O, et al. Detection of laminin 5-specific auto-antibodies in mucous membrane and bullous pemphigoid sera by ELISA. J Invest Dermatol 2005; 124:732.</a></li><li><a class="nounderline abstract_t">Goletz S, Probst C, Komorowski L, et al. A sensitive and specific assay for the serological diagnosis of antilaminin 332 mucous membrane pemphigoid. Br J Dermatol 2019; 180:149.</a></li><li><a class="nounderline abstract_t">Kelly SE, Wojnarowska F. The use of chemically split tissue in the detection of circulating anti-basement membrane zone antibodies in bullous pemphigoid and cicatricial pemphigoid. Br J Dermatol 1988; 118:31.</a></li><li><a class="nounderline abstract_t">Setterfield J, Shirlaw PJ, Kerr-Muir M, et al. Mucous membrane pemphigoid: a dual circulating antibody response with IgG and IgA signifies a more severe and persistent disease. Br J Dermatol 1998; 138:602.</a></li><li><a class="nounderline abstract_t">Roussel A, Benichou J, Randriamanantany ZA, et al. Enzyme-linked immunosorbent assay for the combination of bullous pemphigoid antigens 1 and 2 in the diagnosis of bullous pemphigoid. Arch Dermatol 2011; 147:293.</a></li><li><a class="nounderline abstract_t">Sitaru C, Dähnrich C, Probst C, et al. Enzyme-linked immunosorbent assay using multimers of the 16th non-collagenous domain of the BP180 antigen for sensitive and specific detection of pemphigoid autoantibodies. Exp Dermatol 2007; 16:770.</a></li><li><a class="nounderline abstract_t">Kobayashi M, Amagai M, Kuroda-Kinoshita K, et al. BP180 ELISA using bacterial recombinant NC16a protein as a diagnostic and monitoring tool for bullous pemphigoid. J Dermatol Sci 2002; 30:224.</a></li><li><a class="nounderline abstract_t">Schmidt E, Obe K, Bröcker EB, Zillikens D. Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Arch Dermatol 2000; 136:174.</a></li><li><a class="nounderline abstract_t">Charneux J, Lorin J, Vitry F, et al. Usefulness of BP230 and BP180-NC16a enzyme-linked immunosorbent assays in the initial diagnosis of bullous pemphigoid: a retrospective study of 138 patients. Arch Dermatol 2011; 147:286.</a></li><li><a class="nounderline abstract_t">Fairley JA, Bream M, Fullenkamp C, et al. Missing the target: characterization of bullous pemphigoid patients who are negative using the BP180 enzyme-linked immunosorbant assay. J Am Acad Dermatol 2013; 68:395.</a></li><li><a class="nounderline abstract_t">Nakama K, Koga H, Ishii N, et al. Clinical and Immunological Profiles of 14 Patients With Bullous Pemphigoid Without IgG Autoantibodies to the BP180 NC16A Domain. JAMA Dermatol 2018; 154:347.</a></li><li><a class="nounderline abstract_t">Wieland CN, Comfere NI, Gibson LE, et al. Anti-bullous pemphigoid 180 and 230 antibodies in a sample of unaffected subjects. Arch Dermatol 2010; 146:21.</a></li><li><a class="nounderline abstract_t">Wang M, Lehman JS, Camilleri MJ, et al. Circulating bullous pemphigoid autoantibodies in the setting of negative direct immunofluorescence findings for bullous pemphigoid: A single-center retrospective review. J Am Acad Dermatol 2019; 81:472.</a></li><li><a class="nounderline abstract_t">Bernard P, Antonicelli F, Bedane C, et al. Prevalence and clinical significance of anti-laminin 332 autoantibodies detected by a novel enzyme-linked immunosorbent assay in mucous membrane pemphigoid. JAMA Dermatol 2013; 149:533.</a></li><li><a class="nounderline abstract_t">Rashid KA, Gürcan HM, Ahmed AR. Antigen specificity in subsets of mucous membrane pemphigoid. J Invest Dermatol 2006; 126:2631.</a></li><li><a class="nounderline abstract_t">Chan LS, Majmudar AA, Tran HH, et al. Laminin-6 and laminin-5 are recognized by autoantibodies in a subset of cicatricial pemphigoid. J Invest Dermatol 1997; 108:848.</a></li><li><a class="nounderline abstract_t">Lazarova Z, Yee C, Lazar J, Yancey KB. IgG autoantibodies in patients with anti-epiligrin cicatricial pemphigoid recognize the G domain of the laminin 5 alpha-subunit. Clin Immunol 2001; 101:100.</a></li><li><a class="nounderline abstract_t">Amber KT, Bloom R, Hertl M. A systematic review with pooled analysis of clinical presentation and immunodiagnostic testing in mucous membrane pemphigoid: association of anti-laminin-332 IgG with oropharyngeal involvement and the usefulness of ELISA. J Eur Acad Dermatol Venereol 2016; 30:72.</a></li><li><a class="nounderline abstract_t">Ali S, Kelly C, Challacombe SJ, et al. Salivary IgA and IgG antibodies to bullous pemphigoid 180 noncollagenous domain 16a as diagnostic biomarkers in mucous membrane pemphigoid. Br J Dermatol 2016; 174:1022.</a></li><li><a class="nounderline abstract_t">Kulthanan K, Chularojanamontri L, Tuchinda P, et al. Prevalence and clinical features of Thai patients with bullous pemphigoid. Asian Pac J Allergy Immunol 2011; 29:66.</a></li><li><a class="nounderline abstract_t">Bushkell LL, Jordon RE. Bullous pemphigoid: a cause of peripheral blood eosinophilia. J Am Acad Dermatol 1983; 8:648.</a></li><li><a class="nounderline abstract_t">Borrego L, Maynard B, Peterson EA, et al. Deposition of eosinophil granule proteins precedes blister formation in bullous pemphigoid. Comparison with neutrophil and mast cell granule proteins. Am J Pathol 1996; 148:897.</a></li><li><a class="nounderline abstract_t">D'Auria L, Pietravalle M, Mastroianni A, et al. IL-5 levels in the serum and blister fluid of patients with bullous pemphigoid: correlations with eosinophil cationic protein, RANTES, IgE and disease severity. Arch Dermatol Res 1998; 290:25.</a></li><li><a class="nounderline abstract_t">Arbesman CE, Wypych JI, Reisman RE, Beutner EH. IgE levels in sera of patients with pemphigus or bullous pemphigoid. Arch Dermatol 1974; 110:378.</a></li><li><a class="nounderline abstract_t">Freire PC, Muñoz CH, Stingl G. IgE autoreactivity in bullous pemphigoid: eosinophils and mast cells as major targets of pathogenic immune reactants. Br J Dermatol 2017; 177:1644.</a></li><li><a class="nounderline abstract_t">Ambros-Rudolph CM, Black MM. From prurigo gestationis Besnier to atopic eruption of pregnancy: the confusing nosology of the less well-defined dermatoses of pregnancy has been largely clarified. Clin Dermatol 2006; 24:545.</a></li><li><a class="nounderline abstract_t">Ambros-Rudolph CM, Müllegger RR, Vaughan-Jones SA, et al. The specific dermatoses of pregnancy revisited and reclassified: results of a retrospective two-center study on 505 pregnant patients. J Am Acad Dermatol 2006; 54:395.</a></li><li><a class="nounderline abstract_t">Giudice GJ, Wilske KC, Anhalt GJ, et al. Development of an ELISA to detect anti-BP180 autoantibodies in bullous pemphigoid and herpes gestationis. J Invest Dermatol 1994; 102:878.</a></li><li><a class="nounderline abstract_t">Zillikens D, Kawahara Y, Ishiko A, et al. A novel subepidermal blistering disease with autoantibodies to a 200-kDa antigen of the basement membrane zone. J Invest Dermatol 1996; 106:1333.</a></li><li><a class="nounderline abstract_t">Dilling A, Rose C, Hashimoto T, et al. Anti-p200 pemphigoid: a novel autoimmune subepidermal blistering disease. J Dermatol 2007; 34:1.</a></li><li><a class="nounderline abstract_t">Meijer JM, Diercks GF, Schmidt E, et al. Laboratory Diagnosis and Clinical Profile of Anti-p200 Pemphigoid. JAMA Dermatol 2016; 152:897.</a></li><li><a class="nounderline abstract_t">Groth S, Recke A, Vafia K, et al. Development of a simple enzyme-linked immunosorbent assay for the detection of autoantibodies in anti-p200 pemphigoid. Br J Dermatol 2011; 164:76.</a></li><li><a class="nounderline abstract_t">García-Díez I, Martínez-Escala ME, Ishii N, et al. Usefulness of a Simple Immunohistochemical Staining Technique to Differentiate Anti-p200 Pemphigoid From Other Autoimmune Blistering Diseases: A Report of 2 Cases. Actas Dermosifiliogr 2017; 108:e1.</a></li><li><a class="nounderline abstract_t">Martín JM, Pinazo I, Molina I, et al. Cicatricial pemphigoid of the Brunsting-Perry type. Int J Dermatol 2009; 48:293.</a></li><li><a class="nounderline abstract_t">Jedlickova H, Niedermeier A, Zgažarová S, Hertl M. Brunsting-Perry pemphigoid of the scalp with antibodies against laminin 332. Dermatology 2011; 222:193.</a></li><li><a class="nounderline abstract_t">Fukuda S, Tsuruta D, Uchiyama M, et al. Brunsting-Perry type pemphigoid with IgG autoantibodies to laminin-332, BP230 and desmoplakins I/II. Br J Dermatol 2011; 165:433.</a></li></ol></div><div id="topicVersionRevision">Topic 16176 Version 18.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21605808" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Clinical features and practical diagnosis of bullous pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28247089" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Bullous Pemphigoid: A Review of its Diagnosis, Associations and Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21923615" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Pemphigoid diseases: pathogenesis, diagnosis, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33684496" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Subepithelial autoimmune blistering dermatoses: Clinical features and diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18159905" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Bullous pemphigoid: physiopathology, clinical features and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16488290" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The specificity and sensitivity of Nikolskiy sign in the diagnosis of pemphigus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24424192" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Diagnosis and classification of pemphigus and bullous pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24434358" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Diagnosis and classification of autoimmune blistering diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31351883" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Pathophysiologic mechanisms of itch in bullous pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10891967" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Pemphigoid: clinical, histologic, immunopathologic, and therapeutic considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30624571" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Assessment of the Prevalence of Mucosal Involvement in Bullous Pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24238190" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Onychomadesis during bullous pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21605819" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Nail involvement in autoimmune bullous disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16336529" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Localized bullous pemphigoid: a commonly delayed diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1469147" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Localized pretibial pemphigoid and pemphigoid nodularis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8408921" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Localized bullous pemphigoid: report of a case with an immunofluorescence and electron microscopical studies on the lesional distribution of 180-KD bullous pemphigoid antigen, beta 4 integrin, and type VII collagen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17725660" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Localized pemphigoid (pretibial type) with IgG antibody to BP180 NC16a domain successfully treated with minocycline and topical corticosteroid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17584328" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Case of localized bullous pemphigoid with unique clinical manifestations in the lower legs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8854594" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Localized bullous pemphigoid of the vulva.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1599268" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Childhood localized vulvar pemphigoid is a true variant of bullous pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21860176" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Localized bullous pemphigoid at urostomy site.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9118756" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Bullous pemphigoid at colostomy site: report of a case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7671407" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Bullous pemphigoid following radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17161479" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Radiation-induced bullous pemphigoid: a systematic review of an unusual radiation side effect.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7913427" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Bullous pemphigoid initially localized to sites of burns (scalds) in a patient on sulphasalazine for ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2686871" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Trauma-induced bullous pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3545091" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Localized bullous pemphigoid. A mimic of acute contact dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24125034" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Postvaccination bullous pemphigoid in infancy: report of three new cases and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24861031" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Relationship between radiation therapy and bullous pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3552190" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Cutaneous involvement in localized forms of bullous pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23804286" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Bullous pemphigoid as pruritus in the elderly: a common presentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23804286" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Bullous pemphigoid as pruritus in the elderly: a common presentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28215664" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Generalised nodules in pemphigoid nodularis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31009674" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Nonbullous pemphigoid: Insights in clinical and diagnostic findings, treatment responses, and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30624575" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Assessment of Diagnostic Strategy for Early Recognition of Bullous and Nonbullous Variants of Pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10417629" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Autoantibodies in lichen planus pemphigoides react with a novel epitope within the C-terminal NC16A domain of BP180.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18988318" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Pemphigoid vegetans: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8436652" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Pemphigoid vegetans represents a bullous pemphigoid variant. Patient's IgG autoantibodies identify the major bullous pemphigoid antigen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15202856" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Dyshidrosiform bullous pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33924249" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Dyshidrosiform Bullous Pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17269979" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Vesicular pemphigoid with circulating autoantibodies against 230-kDa and 180-kDa proteins, and additional autoantibodies against 97-kDa and 45-kDa proteins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30484821" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Association of Transient Palmoplantar Keratoderma With Clinical and Immunologic Characteristics of Bullous Pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11902988" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3516897" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Cicatricial pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11004612" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Cicatricial pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28485892" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Multimorbidity in bullous pemphigoid: a case-control analysis of bullous pemphigoid patients with age- and gender-matched controls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27343837" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Hospitalization, inpatient burden and comorbidities associated with bullous pemphigoid in the U.S.A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30234116" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Comorbidities and Treatment Strategies in Bullous Pemphigoid: An Appraisal of the Existing Litterature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24979241" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : A retrospective consecutive case-series study on the effect of systemic treatment, length of admission time, and co-morbidities in 98 bullous pemphigoid patients admitted to a tertiary centre.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23199326" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Prothrombotic state and impaired fibrinolysis in bullous pemphigoid, the most frequent autoimmune blistering disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26245987" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Increased risk of venous thromboembolism in patients with bullous pemphigoid. The INVENTEP (INcidence of VENous ThromboEmbolism in bullous Pemphigoid) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33640889" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : A History of Asthma Increases the Risk of Bullous Pemphigoid: Insights from a Large Population-Based Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30216411" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Cancer is not a risk factor for bullous pemphigoid: 10-year population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11358730" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Bullous pemphigoid in a leg affected with hemiparesia: a possible relation of neurological diseases with bullous pemphigoid?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21085189" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : The relationship between neurological disease and bullous pemphigoid: a population-based case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20944650" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Risk factors for bullous pemphigoid in the elderly: a prospective case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2663936" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Bullous pemphigoid and multiple sclerosis: more than a coincidence? Report of three cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8857334" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Bullous pemphigoid and multiple sclerosis: a report of three cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11872420" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Multiple sclerosis and bullous pemphigoid: a casual association or a pathogenetic correlation?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18573841" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Autoimmune diseases in patients with multiple sclerosis and their first-degree relatives: a nationwide cohort study in Denmark.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25651418" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Neurological disorders in patients with bullous pemphigoid: clinical and experimental investigations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26434420" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : A review of case-control studies on the risk factors for the development of autoimmune blistering diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27599898" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Bullous pemphigoid and its association with neurological diseases: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27477403" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : A Potential Link between Amyotrophic Lateral Sclerosis and Bullous Pemphigoid: Six New Cases and a Systematic Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28681724" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : The association between bullous pemphigoid and neurological disorders: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20463037" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Autoimmune diseases prior to the diagnosis of multiple sclerosis: a population-based case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31820332" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Neurological Cancer is a Risk Factor for Bullous Pemphigoid: 11-Year Population-Based Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15914253" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Humoral immunity in brain aging and Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20664178" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Sera of elderly bullous pemphigoid patients with associated neurological diseases recognize bullous pemphigoid antigens in the human brain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19416254" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Sera from patients with bullous pemphigoid (BP) associated with neurological diseases recognized BP antigen 1 in the skin and brain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28101965" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : A multi-hit hypothesis of bullous pemphigoid and associated neurological disease: Is HLA-DQB1*03:01, a potential link between immune privileged antigen exposure and epitope spreading?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28627382" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : BPAG1, a distinctive role in skin and neurological diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11410196" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Anti-epiligrin cicatricial pemphigoid and relative risk for cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17467241" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : A widening perspective regarding the relationship between anti-epiligrin cicatricial pemphigoid and cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33811327" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Clinical and immunological findings in 55 patients with anti-laminin 332-type mucous membrane pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31106014" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Mucous Membrane Pemphigoid-Associated Malignancies: Case Series and a Brief Overview of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16441418" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Laminin-5 (laminin-332): Unique biological activity and role in tumor growth and invasion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23806157" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Bullous pemphigoid: associations and management guidelines: facts and controversies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25671805" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Association of Bullous Pemphigoid and Malignant Neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28645646" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Association of bullous pemphigoid with malignancy: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29313891" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Association between bullous pemphigoid and malignancy: A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20579597" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Autoimmune blistering diseases in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12775979" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Childhood bullous pemphigoid: a clinicopathologic study and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27086740" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Neonatal Autoimmune Blistering Disease: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14616835" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Comparison of immunofluorescence microscopy, immunoblotting and enzyme-linked immunosorbent assay methods in the laboratory diagnosis of bullous pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23969034" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Comparative study of direct and indirect immunofluorescence and of bullous pemphigoid 180 and 230 enzyme-linked immunosorbent assays for diagnosis of bullous pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33909024" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Assessment of Diagnostic Strategy for Mucous Membrane Pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20713186" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Modern diagnosis of autoimmune blistering skin diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25348760" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Biopsy location for direct immunofluorescence in patients with suspected bullous pemphigoid impacts probability of a positive test result.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32506435" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Diagnostic performance of direct immunofluorescence microscopy studies by biopsy sites in autoimmune subepidermal blistering dermatoses: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32618708" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : False-Negative Rate of Direct Immunofluorescence on Lower Extremities in Bullous Pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3882783" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Effect of anatomic region on immunofluorescence diagnosis of bullous pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2645321" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Direct immunofluorescence in bullous pemphigoid: effects of extent and location of lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2279342" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Determination of the optimum site for diagnostic biopsy for direct immunofluorescence in bullous pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29681159" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Bullous Pemphigoid: A 10-Year Study of Discordant Results on Direct Immunofluorescence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29681159" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Bullous Pemphigoid: A 10-Year Study of Discordant Results on Direct Immunofluorescence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32490114" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Immunoglobulin M bullous pemphigoid: An enigma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28676329" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Multiple and repeated sampling increases the sensitivity of direct immunofluorescence testing for the diagnosis of mucous membrane pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21711326" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Detection of linear IgE deposits in bullous pemphigoid and mucous membrane pemphigoid: a useful clue for diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15270879" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : U-serrated immunodeposition pattern differentiates type VII collagen targeting bullous diseases from other subepidermal bullous autoimmune diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21692774" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Immunofluorescence serration pattern analysis as a diagnostic criterion in antilaminin-332 mucous membrane pemphigoid: immunopathological findings and clinical experience in 10 Dutch patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21430884" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Salt split technique: a useful tool in the diagnosis of subepidermal bullous disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30953703" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Anti-p200 pemphigoid is the most common pemphigoid disease with serum antibodies against the dermal side by indirect immunofluorescence microscopy on human salt-split skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7986125" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Antiepiligrin cicatricial pemphigoid. A subepithelial bullous disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1401088" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Epiligrin, the major human keratinocyte integrin ligand, is a target in both an acquired autoimmune and an inherited subepidermal blistering skin disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15816831" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Detection of laminin 5-specific auto-antibodies in mucous membrane and bullous pemphigoid sera by ELISA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30216412" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : A sensitive and specific assay for the serological diagnosis of antilaminin 332 mucous membrane pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3277659" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : The use of chemically split tissue in the detection of circulating anti-basement membrane zone antibodies in bullous pemphigoid and cicatricial pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9640363" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Mucous membrane pemphigoid: a dual circulating antibody response with IgG and IgA signifies a more severe and persistent disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21422336" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Enzyme-linked immunosorbent assay for the combination of bullous pemphigoid antigens 1 and 2 in the diagnosis of bullous pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17697150" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Enzyme-linked immunosorbent assay using multimers of the 16th non-collagenous domain of the BP180 antigen for sensitive and specific detection of pemphigoid autoantibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12443845" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : BP180 ELISA using bacterial recombinant NC16a protein as a diagnostic and monitoring tool for bullous pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10677092" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21422334" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Usefulness of BP230 and BP180-NC16a enzyme-linked immunosorbent assays in the initial diagnosis of bullous pemphigoid: a retrospective study of 138 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23083837" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Missing the target: characterization of bullous pemphigoid patients who are negative using the BP180 enzyme-linked immunosorbant assay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29299596" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Clinical and Immunological Profiles of 14 Patients With Bullous Pemphigoid Without IgG Autoantibodies to the BP180 NC16A Domain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20083688" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Anti-bullous pemphigoid 180 and 230 antibodies in a sample of unaffected subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30928465" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Circulating bullous pemphigoid autoantibodies in the setting of negative direct immunofluorescence findings for bullous pemphigoid: A single-center retrospective review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23426192" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Prevalence and clinical significance of anti-laminin 332 autoantibodies detected by a novel enzyme-linked immunosorbent assay in mucous membrane pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16810295" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Antigen specificity in subsets of mucous membrane pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9182809" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Laminin-6 and laminin-5 are recognized by autoantibodies in a subset of cicatricial pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11580232" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : IgG autoantibodies in patients with anti-epiligrin cicatricial pemphigoid recognize the G domain of the laminin 5 alpha-subunit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26446477" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : A systematic review with pooled analysis of clinical presentation and immunodiagnostic testing in mucous membrane pemphigoid: association of anti-laminin-332 IgG with oropharyngeal involvement and the usefulness of ELISA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26676445" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Salivary IgA and IgG antibodies to bullous pemphigoid 180 noncollagenous domain 16a as diagnostic biomarkers in mucous membrane pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21560490" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Prevalence and clinical features of Thai patients with bullous pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6345605" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Bullous pemphigoid: a cause of peripheral blood eosinophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8774144" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Deposition of eosinophil granule proteins precedes blister formation in bullous pemphigoid. Comparison with neutrophil and mast cell granule proteins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9522998" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : IL-5 levels in the serum and blister fluid of patients with bullous pemphigoid: correlations with eosinophil cationic protein, RANTES, IgE and disease severity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4217592" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : IgE levels in sera of patients with pemphigus or bullous pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28868796" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : IgE autoreactivity in bullous pemphigoid: eosinophils and mast cells as major targets of pathogenic immune reactants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17113973" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : From prurigo gestationis Besnier to atopic eruption of pregnancy: the confusing nosology of the less well-defined dermatoses of pregnancy has been largely clarified.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16488288" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : The specific dermatoses of pregnancy revisited and reclassified: results of a retrospective two-center study on 505 pregnant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7516396" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Development of an ELISA to detect anti-BP180 autoantibodies in bullous pemphigoid and herpes gestationis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8752680" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : A novel subepidermal blistering disease with autoantibodies to a 200-kDa antigen of the basement membrane zone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17204094" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Anti-p200 pemphigoid: a novel autoimmune subepidermal blistering disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27167149" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Laboratory Diagnosis and Clinical Profile of Anti-p200 Pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20854435" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Development of a simple enzyme-linked immunosorbent assay for the detection of autoantibodies in anti-p200 pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27095685" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Usefulness of a Simple Immunohistochemical Staining Technique to Differentiate Anti-p200 Pemphigoid From Other Autoimmune Blistering Diseases: A Report of 2 Cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19261020" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Cicatricial pemphigoid of the Brunsting-Perry type.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21228551" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Brunsting-Perry pemphigoid of the scalp with antibodies against laminin 332.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21457206" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Brunsting-Perry type pemphigoid with IgG autoantibodies to laminin-332, BP230 and desmoplakins I/II.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
